Treatment of malignant gastrointestinal- and biliary obstructions with metal stents by Larssen, Lene
    
 
Treatment of malignant       
gastrointestinal- and biliary 
obstructions with metal stents 
                                          Lene Larssen
                      Department of Gastroenterology 
                     Oslo University Hospital, Ullevål
                                                               
                                          2013
                     
                   
                   
                                                                                                       
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Lene Larssen, 2013 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 1667 
 
ISBN 978-82-8264-610-9 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AIT Oslo AS.  
 
Produced in co-operation with Akademika Publishing.  
The thesis is produced by Akademika Publishing merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
3 
 
Table of Contents
Table of Contents............................................................................................................ 3
Acknowledgements......................................................................................................... 5
Abbreviations.................................................................................................................. 7
List of papers................................................................................................................... 8
Paper 1 ......................................................................................................................... 8
Paper 2 ......................................................................................................................... 8
Paper 3 ......................................................................................................................... 8
Paper 4 ......................................................................................................................... 9
Paper 5 ......................................................................................................................... 9
Thesis at a glance .......................................................................................................... 10
Introduction................................................................................................................... 11
Palliative treatment of malignant GI-and biliary obstruction.................................... 12
Evaluation of the clinical outcome of SEMS treatment ............................................ 17
Objective evaluation of SEMS effect ........................................................................ 18
Colonic stents as a bridge to elective surgery ........................................................... 19
Aims.............................................................................................................................. 20
Patients and study design .............................................................................................. 22
Patients....................................................................................................................... 22
Study design .............................................................................................................. 24
Methods......................................................................................................................... 25
Patient reported Quality of life .................................................................................. 25
Physician reported outcome ...................................................................................... 27
Endoscopic procedure ............................................................................................... 27
Octanoic acid gastric emptying breath test................................................................ 28
Statistical methods..................................................................................................... 29
Ethics ......................................................................................................................... 30
Summary of papers ....................................................................................................... 31
Paper 1: ...................................................................................................................... 31
Paper 2: ...................................................................................................................... 31
Paper 3: ...................................................................................................................... 32
Paper 4: ...................................................................................................................... 33
Paper 5: ...................................................................................................................... 34
Methodological considerations.................................................................................. 35
4 
 
Patients .................................................................................................................. 35
Study design.......................................................................................................... 35
Patient reported outcomes..................................................................................... 36
Physician reported outcomes ................................................................................ 38
Long-term outcomes ............................................................................................. 38
The octanoic acid breath test of gastric emptying ................................................ 39
Discussion of results.................................................................................................. 40
Patient reported outcomes..................................................................................... 40
Long –term outcomes ........................................................................................... 42
Gastroduodenal stents effect on gastric emptying ................................................ 45
Colonic stents as a bridge to surgery .................................................................... 46
Conclusions................................................................................................................... 48
Clinical implications ..................................................................................................... 51
Future perspectives ....................................................................................................... 52
Erratum ......................................................................................................................... 53
Appendices.................................................................................................................... 54
References..................................................................................................................... 59
5 
 
Acknowledgements
The present work was carried out at the Department of Gastroenterology at Oslo 
University Hospital, Ullevål, Norway during the time period 2006- 2012.   During the 
study period I worked as a consultant at the Department of Gastroenterology, Oslo 
University Hospital and as a research fellow with funding form the Faculty of 
Medicine, University of Oslo.
I want to express my deepest gratitude to all the patients and their relatives, who were 
willing to participate in this study, despite of their often great symptomatic burden and 
limited life expectancy. 
I am most grateful to: 
My supervisor Truls Hauge, who challenged and encouraged me to start this scientific 
project, which would have been impossible to conduct without his enthusiasm, 
knowledge, experience and broad network of collaborators.
My co-supervisor Asle W. Medhus, who always was available for inspiring 
discussions, and guided me through all faces of this work with invaluable knowledge 
and scientific insight.
My co-supervisor Arild Nesbakken, who contributed with great knowledge in the 
planning and conduction of the study and provided excellent guidance in the process 
of learning to analyze and publish science.
This study would not have been realized without the efforts of numerous physicians 
and nurses at the eight collaborating Norwegian hospitals: Stavanger University 
Hospital, Østfold Hospital Trust, Fredrikstad, Vestre Viken Hospital Trust, Drammen, 
Innlandet Hospital Trust, Gjøvik, Innlandet Hospital Trust, Lillehammer, Nord-
Trøndelag Hospital Trust, Levanger, Aker University Hospital and AHUS University 
Hospital. 
I especially would like to express my gratitude towards my co-authors:  Hartwig 
Körner, Tom Glomsaker, Taran Søberg, Dagfinn Gleditsch, Øistein Hovde, Jan K. 
Tholfsen and Knut Skreden, who organized the recruitment of patients, patiently 
6 
 
supplied me with information and gave me important feedback and support during the 
publication process. 
Thanks to co-author Marianne N. Hjermstad at Regional Centre for Excellence in 
Palliative Care, South Eastern Norway and to Jon Håvard Loge, The faculty of 
Medicine, Oslo, for sharing their enormous knowledge about patients reported 
outcome measures and thus ensured the quality of our data.
Statistical help by Leiv Sandvik, Section of Biostatistics, Epidemiology and Health 
economics OUS, Ullevål is deeply appreciated.
A special thanks to Anne-May Schjønneberg and Grethe Keirung who conducted the 
Octanoic acid breath tests.
I am very thankful towards my leaders, colleges and the whole staff at the Department 
of Gastroenterology, OUS, Ullevål for exceptional support and for creating such a 
good and inspiring working environment.
I also want to express my gratitude towards my fellow PhD students, Margit Brottveit, 
Kristin Kaasen Jørgensen, Siri Feruglio and Astrid Bergrem for making life as a PhD 
student much easier through sharing of frustrations, knowledge and experiences.
Finally, I would like to express my gratitude towards my family and friends for 
patience and strong support.
7 
 
Abbreviations
APC      Argon plasma coagulation 
ASA              American Society of Anesthesiologists
BTS               Bridge to surgery
EORTC         The European Organization for Research and Treatment of Cancer
GE Gastric emptying 
GEA      Gastro-entero-anastomosis
GI Gastrointestinal
GOO      Gastric outlet obstruction
PEG               Percutaneous endoscopic gastrostomy
PRO               Patient reported outcome
PTBD            Percutaneous Transhepatic Biliary Drainage
QLQ       Quality of life questionnaire
QoL      Quality of life
SEMS      Self-expanding metal stent
T50%                 Half emptying time
VAS       Visual analog scale
8 
 
List of papers
 
Paper 1
Treatment of malignant gastric outlet obstruction with stents: an evaluation of 
the reported variables for clinical outcome.
Larssen L, Medhus AW, Hauge T.
BMC Gastroenterol. 2009 Jun 17;9:45. doi: 10.1186/1471-230X-9-45.
Paper 2
Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian 
multicenter study.
Larssen L, Medhus AW, Hjermstad MJ, Körner H, Glomsaker T, Søberg T,
Gleditsch D, Hovde O, Nesbakken A, Tholfsen JK, Skreden K, Hauge T.
Surg Endosc. 2011 Oct;25(10):3162-9
Paper 3
Long-term outcome of palliative treatment with Self-expanding metal stents for 
malignant obstuctions of the GI tract
Lene Larssen MD, Asle W. Medhus MD, PhD, Hartwig Körner MD, PhD, Tom 
Glomsaker MD, Taran Søberg MD, Dagfinn Gleditsch MD, Øistein Hovde MD , Jan 
K. Tholfsen MD, Knut Skreden MD, Arild Nesbakken MD, PhD and Truls Hauge MD, 
PhD
Scand J Gastroenterol. 2012 Dec;47(12):1505-14
9 
 
Paper 4
Stent treatment of malignant gastric outlet obstruction
- The effect on rate of gastric emptying, symptoms and survival
Lene Larssen MD, Truls Hauge MD, PhD and Asle W. Medhus MD, PhD
Surg Endosc. 2012 Oct;26(10):2955-60
Paper 5
Stenting as a bridge to surgery is safe and effective in acute malignant left-sided 
large bowel obstruction 
Lene Larssen MD, Asle W. Medhus MD, PhD, Hartwig Körner MD, PhD, Tom 
Glomsaker MD, PhD, Taran Søberg MD, Dagfinn Gleditsch MD, Øistein Hovde 
MD1, Jan K. Tholfsen MD, Knut Skreden MD, Arild Nesbakken MD, PhD and Truls 
Hauge MD, PhD.1,2 
Submitted
10 
 
Thesis at a glance 
Aim Patients and methods Results Conclusion
I
To review how is 
treatment 
outcome after 
gastroduodenal 
stents evaluated
Review of publications 
between 2000 and 2008 
regarding palliative 
treatment of 
gastroduodenal 
obstruction with stents.
18 out of 45 
publications had used
a graded symptom 
scale to evaluate stent 
effect No studies had 
used PRO to evaluate 
effect. No studies had 
objectively evaluated 
stent effect.
Available reports do not 
provide sufficient 
relevant information of 
the clinical outcome of 
duodenal stenting. 
II
To study how 
patients evaluate 
the clinical effect
of palliative stent 
treatment by
using PRO/QoL
162 patients treated 
with metal stents for 
gastrointestinal- and 
biliary obstruction at 9
Norwegian hospitals 
from 2006 until 2008 
were included. QLQ
were completed before 
and 2 weeks after 
treatment.
Significant clinical 
improvement in 
obstruction related 
symptoms and global 
health were found for
all 4 stent locations.
Physicians reported a 
larger improvement 
than the patients.
SEMS treatment is 
effective in relieving 
symptoms of malignant
GI and biliary 
obstruction.  Both 
according to patients and 
physicians, physicians 
reported the largest 
effect.
III
To evaluate long-
term outcome 
after stent 
treatment , with 
special focus on 
need for 
reinterventions 
and 
rehospitalizations
219 patients palliatively 
treated with metal stents 
were followed for at 
least 6 months after 
treatment
33 % needed 
reinterventions, most 
often for 
reobstruction, 
esophageal stents 
most frequently. 72 % 
needed readmissions, 
only 25 % for stent 
complications.
Palliative stenting of 
malignant 
gastrointestinal 
obstruction is safe and
effective.
IV
To study how 
gastroduodenal 
stents effects the 
gastric emptying 
rate
17 patients underwent 
gastric emptying test 
before and after 
treatment with 
gastroduodenal stents
Gastric emptying 
improved 
significantly. There 
was no correlation 
between survival and 
rate of gastric 
emptying before, after 
or change in rate of 
emptying.
SEMS treatment results 
in improved gastric 
emptying in most 
patients with GOO.
V
To evaluate the 
safety and 
efficiency of 
colonic stents as a 
bridge to surgery
46 patients with 
malignant colonic 
obstruction were
included with intention 
BTS, 43 with left sided 
colon obstructions
34 patients underwent 
elective surgery after 
stent. Stenting as BTS 
was successful in 
77 %, with procedure 
related bowel 
perforation rate of 
only 5 % and no 
mortality.
Emergency stenting of 
colorectal obstruction 
was safe and effectively 
prevented diverting 
stomas.
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Introduction
Every year around 5000 new cases of gastrointestinal cancer (GI) are diagnosed in 
Norway, which accounts for 25 % of all cancer cases. The incidence rate of 
esophageal – and colorectal cancer is increasing, but the rate of non-cardiac gastric 
cancer is decreasing. Cancers located in other parts of the GI tract have more stable 
incidences 1. The cancer survival rate has generally increased due to earlier detection 
and better treatment regimes, but still 40-80 % of patients have cancer at such 
advanced stages at the time of diagnosis that only palliative treatment can be offered 2-
4.
Obstruction is a common problem in advanced stages of GI- and biliary cancers. Most 
patients with advanced esophageal cancer will develop some degree of dysphagia and 
50 % of patients with will need a stent during the course of the disease 5. Malignant 
gastric outlet obstruction (GOO) is commonly seen in patients with advanced gastric-, 
pancreatic-, duodenal, hepato-biliary or metastatic malignancies. GOO causes nausea 
and vomiting, and can lead to dehydration and cachexia, which severely reduces the 
patients’ Quality of Life (QoL). Ten to 25 % of patients with pancreatic cancer will 
develop duodenal obstruction and 70-80 % biliary obstruction during the course of the 
disease 3;6-8.
Primary biliary duct cancer (cholangiocarcinoma) and other malignancies causing 
biliary obstruction ( gallbladder cancer, metastatic cancer disease) are usually 
diagnosed at an advanced stage when only palliative treatment can be offered  9.
Obstruction of bile flow to the duodenum can lead to, itching and icteric discoloration 
of the skin that can be socially stigmatizing and serious infections.
Colorectal cancer have a debut with acute bowel obstruction in 10-30 % 10;11, whereas 
20-50 % of patients with ovarian cancer experiences symptoms of large bowel 
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obstruction 12. Complete obstruction of the large bowel is a life threatening condition 
that needs emergency intervention. 
Palliative treatment of malignant GI-and biliary obstruction
Patients diagnosed with malignant GI obstructions often have advanced cancer which 
implies that curative treatment or prolongation of life no longer is possible.  Effective 
palliation from distressing symptoms becomes pivotal for the patients when life 
expectancy is limited. Rapid relief from distressing symptoms, time outside hospital, 
and absence of complications are important factors that are believed to strongly 
influence the patients QoL. Several factors needs consideration in order to make 
decisions about the best palliative option: i.e. age, expected survival, co-morbidities, 
the patients’ wishes, severity of symptoms, location of stenosis and available medical 
expertise. In clinical practice it is important to predict expected survival in order to 
choose the right palliative treatment. This can be difficult 13-15, but all the more 
important, since we should not expose patients with a short life expectancy to 
unnecessary procedures with potential serious complications. 
A multidisciplinary approach, preferable early in the course of the disease, is believed 
to be an advantage 16. The approach to palliative treatment of malignant GI 
obstructions has changed significantly over the last 20 years.  Open surgical 
procedures have been replaced by endoscopic, interventional radiologic and 
laparoscopic surgical procedures and this has led to a significant decrease in 
procedure related morbidity and mortality, discussed in more detail below.
Patients with advanced esophageal cancer often experiences dysphagia which leads to 
nutritional deficiency. Palliative esophageal resections are rarely performed because of 
a high risk of complications 17. For some patients a nasogastric feeding tube or a
percutaneous endoscopic gastrostomy (PEG) can offer good palliation and maintain 
enteral nutrition for a shorter time period. For patients with longer life expectancy,
however, will the inability to swallow, at least liquids and their own saliva be very 
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distressing, even if nutritional status is maintained though a tube or PEG. Therefore
reestablishment of passage with self- expanding metal stent (SEMS) has become the
first choice treatment for many patients with malignant esophageal obstructions. 
Radiation therapy (external or endoluminal) also is frequently used for palliation of
malignant esophageal obstruction. Both methods have a well documented effect on 
dysphagia. SEMS have a more rapid effect on dysphagia while radiation therapy has a
longer lasting effect 18;19. The two treatment modalities are frequently used in 
combination; this is associated with an increased risk of esophago-tracheal fistula 
formation 20.
Gastric outlet obstruction (GOO) leads to nausea, vomiting, aspiration, pain and 
malnutrition which can severely affect quality of life. Simple aspiration of gastric 
contents by a nasogastric tube is often good palliative care for patients with a short life 
expectancy.  For patients with longer expected survival the ability to maintain per oral 
nutrition is very important for the QoL, and we therefore usually attempt restoration of 
gastrointestinal passage.  Endoscopic treatment of malignant GOO with SEMS has to a 
great extent replaced palliative surgery with gastro-entero-anastomosis (GEA). Studies 
comparing gastroduodenal stents with bypass surgery have shown that there are fewer 
serious complications21, less need for care in intensive care units 22, the hospital stay 
is shorter 23;24 and the symptomatic relief is more rapid after SEMS treatment 8;25-28
compared to surgical palliation with GEA 3;29;30.
Palliative surgery for malignant biliary obstructions has been replaced by endoscopic-
(ERCP) or interventional radiologic procedures. The bile can either be drained
externally with Percutaneous Transhepatic Biliary Drainage (PTBD) or internally with 
placement of a stent to the duodenum by an endoscopic procedure, endoscopic 
retrograde cholangiopancreatography (ERCP). Internal drainage is preferable for 
mobile patients with expected survival beyond 3-4 weeks. Both plastic stents and 
SEMS are effective for biliary drainage. Plastic stents are less expensive, but SEMS 
have longer patency and therefore preferred for patients with expected survival > 3 
months who otherwise would need repeated procedures every 3 months 31-34.
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Primary colon cancers and metastatic malignancies may cause obstructions of the large 
bowel that can be life-threatening if complete obstruction occurs. Patients with very 
short life expectancy should receive palliative care with analgetics, anti-emetics, 
steroids,  anti- cholinergic drugs or somatostatin  35. Decompression with a nasogastric 
tube or a PEG can also offer palliation when endoscopic or surgical decompression of 
the colon not is possible. For patients with longer expected survival, however, 
reestablishment of bowel passage is usually attempted. Traditionally has palliative 
surgery with a colostomy been standard treatment for these patients. Emergency 
surgery in these often old and debilitated patents involves a high risk of peri- and post 
operative complications, with mortality rates between 12-25 % 36-39, even up to 40 % 
for patients with high surgical risk (ASA 4) 40. Therefore palliative surgery to a large 
extent has been replaced by endoscopic with SEMS. The stents serve as permanent 
palliative treatment for patients with advanced disease, but can serve as a bridge to 
curative surgery for patients with more limited disease, described in more detail in a 
later section.
Self-expanding metal stents (SEMS)
 
 
Figure 1: Uncoverd colonic SEMS 
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Taking advantage of the technology developed in endovascular stents, gastrointestinal 
stents were introduced in early the 1990 s. The first publications on biliary stents 41;42
were rapidly followed by publications where SEMS had been successfully applied in 
esophagus 43;44 , proximal small intestine 45 and colon 46;47. The first metal stents were 
made of stainless steal, today most SEMS are made of nitinol (an alloy of nickel and 
titanium), which exhibit properties of shape memory and super elasticity that makes 
them more suitable for their purpose. SEMS are produced in different lengths and 
diameters and possesses different expanding forces, depending on the organ in which 
they are to be placed. Precise placement of uncovered stents is crucial since they 
quickly gets incorporated into the tissue and usually are not removable. Occlusion of 
stents by tumor in- and overgrowth though the nitinol mesh is a problem. SEMS that 
are partially or fully covered with a polyurethane membrane have been  developed to 
prevent this, but these stents have a higher rate of migration 48. Palliative treatment 
SEMS is regarded an advanced endoscopic procedure, usually performed by 
experienced endoscopists or radiologists, depending on local expertise. 
Esophageal stents
Esophageal SEMS are used to relieve dysphagia due to malignant obstruction either by
intrinsic or extrinsic compression of the esophagus. The stents can also be used to 
close malignant esophago-tracheal fistulas. They relieve dysphagia rapidly in 89- 99 
% 49-52 of the patients, with an overall complication rate of 25- 50 % 5;49;53-59. The most 
common complications are reobstruction, stent migration and esophago-tracheal fistula 
formation, which usually can be treated with a repeated endoscopic procedure56;60.
Mortality directly related to the procedure is 0.5-2 % 61.
Biliary stents
Biliary SEMS are used in patients with malignant biliary obstruction caused either by 
primary biliary cancer or extrinsic compression by i.e. liver metastasis. Metal stents 
are preferred in patients with a expected survival > 3 months since these stents have a 
longer patency than plastic stents and hence reduce the need for repeated 
procedures 62;63. Covered and partially covered biliary SEMS have been developed to 
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prevent tumor ingrowth, but do not seem to have increased patency compared to 
uncovered stents 64-66.
Gastroduodenal stents
Gastroduodenal SEMS are used to relieve malignant gastric outlet obstruction (GOO)
caused by either distal gastric cancer, pancreatic cancer, periampullary cancers or 
metastatic cancer to this region. The stents offer good symptomatic palliation for close 
to 90 % of patients 6-8;24;67-70, with few serious complications. Around 20 % 
experiences reobstruction8, but this can usually be treated with a repeated endoscopic 
procedure. Simultaneous obstruction of the biliary tract and the proximal small 
intestine is common and can be treated with double stenting. If there is sign of biliary 
obstruction should a biliary metal stent should be placed first if  possible, since the 
papilla Vateri can be difficult to access after a duodenal stent has been inserted 7;71. If
biliary obstruction occurs after a duodenal stent have been placed, can a biliary stent
be placed with the help of a combined radiologic- and endoscopic procedure 
(rendezvous technique) or with a EUS (endoscopic ultrasound) procedure 72;73.
Colonic stents
Colonic SEMS are used for permanent palliation of malignant colonic obstruction as a 
alternative to palliative surgery.  Several studies and reviews have reported a high 
clinical success rate with an acceptable rate of complications 10;74-79. Colonic stents can 
be placed in the whole length of colon, but preferably not closer to the rectum than 4-5
cm, since this is associated with fecal incontinence and pain. Perforation of colon is 
the most dreaded complication, and occurs in 5 % 10;74.  
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Evaluation of the clinical outcome of SEMS treatment
Short- and long-term outcome
Early studies concerning the outcome of SEMS treatment, whether randomized, 
comparative, or merely descriptive, focused on technical success (e.g. correct 
deployment of the stent), clinical success (restored passage), short-term complications 
and cost-effectiveness.  Numerous studies demonstrated the feasibility, safety and 
cost- efficiency of stent treatment on a short term basis 8;33;34;54;68;74;80;81.  Few studies 
had applied a grading scoring of obstructive symptoms, which makes it difficult to 
draw conclusions concerning treatment effect and to compare results.
Modern multimodal treatment of GI cancer, i.e. chemotherapy, anti- angionetic drugs 
and surgery for metastases, have prolonged the survival for patients with advanced 
cancer, colorectal cancer in particular 82-84. Accordingly, the number of patients 
experiencing late SEMS-related complications, e.g. stent occlusion and perforation of 
the colon may increase. Long- term outcomes like reobstruction rate/patency, late 
complications and re-hospitalizations are therefor important and needed evaluation55;56.
Currently, available long-term data are limited, somewhat conflicting and still subject 
to debate7;85;86.
Patient reported outcomes (PRO) measures 
Traditionally, the physicians’ clinical evaluation of symptomatic effect has been the 
main outcome measure of SEMS treatment. It is known form several studies in 
palliative medicine, however, that physicians’ and patients ‘evaluation differ, and 
underestimation of patients’ symptoms by physicians is most common87-93. In clinical 
trials concerning palliative oncology there has been a gradual change from 
curative/non-curative towards patient reported QoL as the main ending point 94;95. The
same outcome measures should be used when evaluating the outcome of palliative
endoscopic- and surgical procedures. In the planning of the present study few 
publications had applied PRO to assess clinical outcome of SEMS treatment 18;19;60;96-98.
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Furthermore, no data comparing patients’ and physicians’ assessments of the clinical 
effect of SEMS treatment were available. 
The term QoL or health related QoL is widely used, but not well defined.  The term 
usually includes aspects of general health, physical functioning, physical symptoms, 
emotional and cognitive functioning and social functioning, but may vary between 
investigators. Many authors prefer the term patient-reported- outcomes (PRO), which 
suggest interest in the full range of outcomes form mental to physical symptoms. A
vide variety of questionnaires developed and validated for the assessment of QoL are
available 99. Some are generic, which means that they can be used irrespective of 
condition, also for healthy people (SF 36, Euro-Qol/EQ-5D)100;101. Others are disease 
specific (EORTC QLQ-C30, EORTC disease- or treatment specific modules, 
Functional Assessment of Cancer Therapy (FACT)102;103 or addressing specific aspects 
of QoL( HADS, McGill Pain Questionnaire (MPQ), Fatigue Inventory (MFI), Bartel 
Index of Disability (BI))104-107. Some are short, developed for everyday clinical 
practice, while others are more complex and extensive and best suited for use in 
clinical research. Often questionnaires are used in combination in order to evaluate 
different aspects of patients’ physical- and psychic functioning. ECOG108 and 
Karnofskys performance scale 109 are tools commonly used to assess patients physical 
functioning are, but these are not considered complete QoL instruments.  Some 
authors develop their own questionnaires to fit their specific study population and
design. This is generally not recommended; since standardized and validated forms 
must be used in order make the results from different studies comparable.
Objective evaluation of SEMS effect 
 
The clinical effect of SEMS treatment is usually evaluated, as described above, by the 
physician or patients’ assessments, by objective tests are not commonly performed. 
Normalization of s- bilirubin is a good objective measure of a clinical successful 
biliary SEMS placement. Passage of contrast is often used to verify reestablishment of 
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passage though gastroduodenal- and colonic SEMS, but scoring to clinical experience 
some patients may still experience symptoms even though passage is reestablished by 
a stent. 
Placement of a gastroduodenal stent through the pylorus is likely to influence the 
complex interplay between the motility of the stomach and the duodenum. The 
functional consequence on gastric emptying has only been examined in one available 
study quantifying gastric emptying after stent treatment110. No studies have, however, 
estimated the effect of the stent by comparing the rate of gastric emptying before and 
after stent treatment with relation to patient reported effect on symptoms and survival.
 
 
Colonic stents as a bridge to elective surgery
 
Figure 2: Bridge to surgery, resected tumor with stent in place
SEMS was primarily introduced as a method for permanent palliation, but the area of 
use has gradually been extended into several other indications. The use of colonic 
SEMS as a bridge to elective surgery for acute malignant left-sided colonic obstruction
20 
 
(BTS) were introduced in the early 1990s 111. Emergency surgery for malignant 
colonic obstruction has a high morbidity and mortality rate, particularly in elderly 
patients with comorbidities39;40;112;113. Furthermore, the surgery often has to be 
performed in two stages with a temporary stoma after the first operation 39;114;115.
Although planned to be temporary, many stomas are never closed 116 and permanent 
stomas are associated with complications and reduced patient reported  QoL117-119.
The use of SEMS to decompress the bowel followed by an elective one - stage 
resection of the tumour with primary anastomosis, the concept of BTS, is therefore an 
attractive alternative. Several observational studies and reviews have shown that 
SEMS as BTS decreases morbidity, mortality and the number of permanent stomas
compared to emergency surgery 10;74;76;120-123.
There are, however, concerns about that the use of SEMS as BTS can adversely affect 
the oncologic outcome in patients treated with curative intent. It has been 
demonstrated that manipulation of cancers by colonoscopy and stenting increases the 
number of circulating tumour cells 124;125, but the clinical consequence of this is not 
known. The worries are that stent insertion or silent perforations might lead to tumor 
seeding and cancer dissemination. Publications on long-term outcome after stents as 
BTS are sparse and not conclusive 86. Randomized trials and studies of long-term
oncologic outcome are needed to clarify these issues.
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Aims
The general aim of this thesis was to increase the knowledge about the clinical 
outcome of SEMS treatment for malignant GI-and biliary obstruction.
The specific aims were:
x To explore whether available reports on SEMS treatment for GOO provides 
sufficient data for evaluation of clinical outcome. 
x To evaluate how patients assess clinical outcome of palliative SEMS treatment 
by using patient reported outcome measures (PRO).
x To compare patient/physician assessments of symptoms and outcome.
x To evaluate and compare the long-term outcome on four different stents 
locations after palliative treatment with SEMS with regard to complication rate, 
re-intervention rate and re-hospitalizations rate.
x To evaluate the effect of gastroduodenal stents on gastric emptying rate in
patients with GOO. 
x To study the relation between survival, gastric emptying and the effect on
symptoms.
x To evaluate use of SEMS as a bridge to surgery (BTS) for acute malignant left-
sided colonic obstruction with regard to complication rate and the rate of 
successful delayed surgical resections.
22 
 
Patients and study design
 
Patients
Paper 2-5
Nine out of 11 Norwegian hospitals, 3 academic- and 6 community hospitals, accepted 
the invitation to participate in the inclusion of patients in this prospective 
observational multi-center study constituting paper 2-5. All participating centers 
performed stent procedures on a regular basis and had one or two dedicated physicians 
that identified eligible candidates for the study and administered the inclusion. The 
hospitals served catchment areas between 75000 and 300000. 
Patients were included consecutively at all participating hospitals from November 
2006 until April 2008 for the study of patient reported outcomes (paper 2), long-term 
outcomes (paper 3) and colonic SEMS as BTS (paper 5).  Patients for the study of 
gastroduodenal SEMS and gastric emptying (paper 4) were recruited only at Oslo 
University Hospital, Ullevål with an extended inclusion period until May 2010.
Figure 3: Flow chart illustrating the included patients’ paper in 2-5. 288 patients were included totally at 9 
participating centers.  
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Paper 2: Patient reported clinical outcome of SEMS treatment
The inclusion criteria for paper 2 were: 1. symptoms related to malignant GI 
obstruction; 2. indication for treatment with metal stents established; 3. fluency in oral 
and written Norwegian; 4. cognitive capability to complete the questionnaires; 5. 
completion of both quality of life questionnaires (QLQs). Patients treated with colonic 
stents as a BTS, who underwent subsequent bowel resection within two weeks, were 
not included in the analyses in paper 2.
Power calculations in paper 2 were based on a mean change in global health score of 
10, which is considered a small - medium clinically noticeable change for the 
patients126. A SD of 15 of, with 90% power and a 5% level of significance, yielded a 
sample size of minimum 26 patients that had to complete both QLQs for each of the 
four stent locations. 
Paper 3: Long-term outcomes after SEMS treatment
Patients treated with SEMS as permanent palliation, with their SEMS in place and 
long-term data available, were included in the study of long-term outcomes (paper 3).
Paper 4: Gastroduodenal SEMS and gastric emptying
Patients with endoscopically verified malignant obstruction of the proximal duodenum
and planned SEMS treatment were recruited consecutively for paper 4. Patients with 
indications of complete gastroduodenal obstruction, or who had undergone endoscopic 
dilatation of the stricture during the last 4 weeks were not considered eligible for 
inclusion.
Change in T1/2 (half emptying time) was used for sample size calculation in paper 4.
To identify a 15 min-difference in T1/2 with a SD of 18 and a standard difference of 
1.67127 with 90 % power and 5% level of significance, a minimum of 17 patients were 
required. A significant change in gastric emptying was defined as a change exceeding 
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20 % based on data on the expected intra- individual variance of the octanoic acid 
breath test 128;129.
Paper 5: Colonic SEMS as BTS
Patients treated with SEMS with the intention BTS for acute malignant left-sided 
colonic obstruction, were included in paper 5. 
Study design
 
Paper 1
Paper 1 was a review of published literature from January 2000 until September 2007 
regarding clinical outcome treatment for GOO with SEMS. The literature search was 
performed combining the following search terms: duodenal stent, malignant duodenal 
obstruction, gastric outlet obstruction, SEMS, and gastro-entero-anastomosis. The 
search was done in Pub Med, Embase, and Cochrane library. 
2QO\SDSHUVWKDWFRPSULVHGSDWLHQWVDQGZHUHZULWWHQLQ(QJOLVKZHUHLQFOXGHG
The identified studies were reviewed with regard to the following parameters: 1. the 
use of a graded scoring system to evaluate clinical outcome; 2. if PRO were used to 
assess clinical outcome; 3. if information on stent patency and survival were provided 
and 4. if objective criteria to evaluate the stent effect had been used.
Paper 2-5
The QoL questionnaires were administered to the study participants upon admission 
by the treating physician or a study nurse.  The same questionnaire was given to the 
patients when leaving the hospital.  The patients assessments in paper 2 were 
completed twice, at inclusion (-2 to +1 day before/after the procedure) and two weeks 
after treatment.  The patients were instructed to complete the second questionnaire two 
weeks after stent treatment and return it by mail.
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Data on long-term outcomes were retrieved by a retrospective review of the patients 
medical journals. Patients were followed until death, surgical intervention with 
removal of SEMS or until at least six months after treatment.  Follow-up visits were 
performed only when needed since we did not want to burden these often severely ill 
patients with unnecessary hospital visits. 
Patients included in paper 4 performed the octanoic breath test of gastric emptying 
(confer below) before treatment. Thereafter, on the same or the following day, patients 
were treated with a stent, and a new gastric emptying test was performed within one 
week.
Patients with acute malignant colonic obstruction, who required emergency treatment, 
in whom SEMS as BTS was found to be indicated, were eligible for inclusion in paper 
5. Patients considered to be at high surgical risk were also included. After discharge
from the hospital the patients were followed according to national guidelines for the 
treatment of colorectal cancer issued by the Norwegian Gastro-Intestinal Cancer 
Group (NGICG), which were the guidelines during the study period.
Methods
Patient reported Quality of life 
 
The European Organization for Research and Treatment of Cancer (EORTC) 
questionnaires were chosen as our tool for assessing patient reported outcomes after 
consulting with a research group that possesses extensive experience with the 
development, use and interpretation of patient reported outcome measures in palliative 
oncology. EORTCs QLQs are developed, validated and frequently used in study 
populations similar to ours and were found to be well suited for the study purposes. 
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The EORTC QLQ-C30 102 is a cancer specific 30-item self-reporting questionnaire 
consisting of both multi-item scales and single-item measures that has been validated 
in Norwegian 130. These include five functional scales (i.e. physical, role, cognitive, 
emotional, and social), three symptom scales (i.e. fatigue, nausea/vomiting, and pain), 
and six single items (i.e. dyspnea, insomnia, appetite loss, constipation, diarrhea, and 
financial problems), as well as two questions where the patients assessed their overall 
health and QoL on a scale from 1-7.  A combination of these two scores results in a 
global health score.
EORTC has in addition to the core questionnaire C30 developed a series of 
organ/cancer specific questionnaires and it is recommended that they are used in 
combination with the core questionnaire C30.  For the purpose of the present study, a 
selection of questions was made from the relevant organ specific modules to reduce 
the respondent burden for these often severely ill and old patients and thereby 
increases compliance and response rate. Questions to be answered by the patients 
receiving esophageal, biliary, and colonic stents were selected from the stomach 
module, EORTC QLQ-STO22;131 the pancreatic, EORTC QLQ-PAN26;132 and the 
colorectal module, EORTC QLQ-CR38,133 respectively. Patients receiving 
gastroduodenal stents did not answer any additional questions as their main 
obstruction related symptoms, nausea and vomiting, were specifically addressed by the 
core questionnaire. The questionnaire used in paper 2 consisted of 38 questions:  
EORTC C-30 + 8 organ specific questions (appendix 2).
Higher scores on the symptom scales and single items from the core questionnaires 
and the organ-specific modules indicated more severe symptoms, while higher scores 
on the functional scales indicate better functioning.  All items were to be answered on 
an ordinal scale ranging from 1 (“Not at all”) to 4 (“Very much”), except for the two 
modified visual analogue scales assessing global health and QoL, which ranged from 1 
to 7.  The time frame was the past seven days.  Scale and item scores were transformed 
into a continuous scale from 0 to 100, as described in the EORTC Scoring Manual.134
A mean score difference of 5-10 is usually regarded as a small but clinically noticeable 
change for the patients, a change from 10-20 as moderate, and >20 as a large clinical 
change 126;135. Results are estimated and reported as a mean effect on a group level.
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Physician reported outcome
 
The physicians assessed the same organ specific symptoms as the patients; at inclusion 
and the second assessment at hospital discharge or two weeks after stent treatment if 
the patient was still hospitalized.
 
Endoscopic procedure
 
 
  
Figure 4: A introducer set with a preloaded stent.                                                                         
The stent procedures were performed by experienced endoscopists. Most stents were 
placed with a combined endoscopic and radiologic procedure, with the exception of 5 
esophageal stents placed only by endoscopic guidance.  Most procedures were 
performed under conscious sedation using titrated doses of midazolam, pethidine or a
short acting opioid (alfentanil or fentanyl). A few procedures required anesthesiology
assisted Propofol® sedation. Firstly the stricture was identified and visualized 
endoscopically or with radio contrast. The length of the stricture was measured either
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by direct vision, with the help of an ERCP-balloon, if the stricture not could be passed 
by the endoscope. Esophageal strictures were marked either by external radio opaque 
markers, internal metal clips or injection of radio opaque marker Lipoidol®. Dilatation 
of malignant strictures is associated with increased risk of perforation, but was 
however sometimes necessary in esophageal strictures to allow passage of the 
introducer system through the stricture. A stiff guidewire was then inserted through the 
working channel of the endoscope and through the stricture at least 20 cm beyond the 
stricture. SEMS are preloaded onto a delivery system that can be introduced though 
the working channel (TTS) of the endoscopes (with the exception of esophageal 
stents). Finally the introducer set could be passed over the guidewire, through the 
stricture into the correct position and deployed. After deployment the SEMS will try to 
expand back to its original shape and size, this happens gradually over 1-2 days., Some
patients can go home after a few hours observation, others are kept in hospital for a 
day or two, depending on the patients health status prior to treatment and degree of 
discomfort after the procedure.
Octanoic acid gastric emptying breath test
 
Figure 5: The octanoic breath test meal consisting of C13 marked egg yolk and bread with butter
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The rate of gastric emptying was measured by administering a solid meal of 1050 kJ 
consisting of 60 g of white bread, 5 g margarine, a one-egg omelet, and 150 ml water. 
The egg yolk included in the meal contained 91 mg 13C-octanoic acid as marker of 
gastric emptying. Breath samples were collected every 15 min until 240 min after meal 
intake and 13C-content was determined by gas chromatographic purification isotope 
ratio mass spectrometry. Variables of gastric emptying were estimated according to 
Ghoos et al136.
Patients scored their sensation of hunger, satiety and nausea on a visual analogue scale 
(VAS) before meal and every 60 min until 240 min after intake 127. They were also 
asked to grade their symptoms related to obstruction (nausea, vomiting, bloating, 
stomach pain, problems eating solid- or soft food or drinking liquids), before and two 
weeks after treatment. The symptoms were selected from EORTCs quality of life 
questionnaires EORTC QLQ-C30 102and EORTC QLQ-STO22 131.
Statistical methods
The results in paper 3 were reported as median (range) for continuous variables, since 
the data were non-normally distributed. In overall survival analyses, deaths from all 
causes were registered as events, and patients were censored at study closure. In stent 
patency analyses, the first reintervention due to stent failure was registered as an event, 
and patients with functioning stents were censored at death or study closure. 
Non-parametric tests were used for comparison of grouped data, Wilcoxon test for two 
related samples and Mann-Whitney U test for independent samples. Kruskal-Wallis 
test was used for comparing more than two independent samples, and Fisher exact test
for analysis of contingency tables. Correlation analyses were performed by Spearman 
correlation. Time- dependent events were calculated using the Kaplan- Meier (KM) 
method, and log rank test was used to compare groups. The level of statistical 
significance was set at p < 0.05 for all analyses. Results were given as median with 10 
and 90 percentiles in brackets unless otherwise stated.
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Statistical analyses were performed with the at the time latest version of the SPSS 
software package (IBM - SPSS Inc. New York, US).
Ethics
The study was approved by the Regional Committee for Medical Research Ethics in 
Southern Norway and the Data Protection Supervisor at Oslo University Hospital, 
Ullevål. All patients received oral and written information about the study. Written 
informed consent was obtained from all participants before inclusion in the study.
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Summary of papers
Paper 1:
Treatment of malignant gastric outlet obstruction with stents: an evaluation of 
the reported variables for clinical outcome.
The published literature regarding treatment of malignant GOO with stents from 2000-
2007 were reviewed to reveal whether the information provided is sufficient to 
evaluate the clinical effects of this treatment.
45 original papers in English were identified. In 18 out of 45 studies some sort of 
graded scoring system was used. No studies used standardized QoL- questionnaires to 
evaluate the clinical outcome of stent treatment.
35/45 studies reported on stent patency and 11/45 had performed an oral contrast 
examination after stent placement. No studies had used objective quantitative tests of 
gastric emptying to evaluate stent effect.
Our review indicated that the available reports at that point in time did not provide 
sufficient relevant information of the clinical outcome of duodenal stenting. Graded 
scoring of symptoms, patient reported outcome and objective assessment of the stent 
effect should be applied to improve the evaluation of stent treatment. 
Paper 2:
 
Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian 
multicenter study.
 
We evaluated clinical outcome in 162 patients palliatively treated with SEMS for
malignant gastrointestinal (GI) – and biliary obstructions. This was done by patient 
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reported outcome measures/ QoL, and by a graded scoring of the obstruction related 
symptoms. Differences in outcome evaluation between the four outcome locations and 
between patients and physicians were compared.
A significant improvement in the mean global health score was observed after two 
weeks (from 9 – 18 on a 0-100 scale, p<0.03) for all stent locations.  Both patients and 
physicians reported a significant reduction in all obstruction related symptoms (>20 on 
the 0-100 scale, p<0.006) after SEMS treatment. The physicians reported a larger 
mean improvement in symptoms than the patients, mainly due to reporting more 
severe symptoms before treatment.
To conclude, SEMS treatment is effective in relieving symptoms of malignant GI and
biliary obstruction, as reported by patients and physicians.  Physicians and patients 
evaluate treatment effects differently and thereby illustrate the importance of taking 
patient reported outcomes into account when evaluating clinical palliative 
interventions.
Paper 3:
 
Long-term outcome of palliative treatment with Self-expanding metal stents for 
malignant obstructions of the GI tract
 
Long-term outcome after palliative stent treatment for malignant esophageal, 
gastroduodenal, biliary and colonic obstructions was evaluated in 219 patients. 
Patients were followed for at least six months with respect to stent patency, 
reinterventions, complications and readmissions to hospital.
72 patients (33%) needed reinterventions. Stent occlusions or migrations (92 %) were 
the most common reasons. Eighty percent of reinterventions were repeated endoscopic 
procedures that successfully restored patency. Esophageal stents required 
reinterventions most frequently (41%), and had a significantly (p= 0.02) shorter 
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patency (median 152 days) compared to other locations (gastroduodenal, 256 days; 
colon, 276 days; biliary, 460 days). 
Readmissions were required for 156 (72%) patients. Progression of the underlying 
cancer was the most common reason, whereas 24 % were readmitted due to stent 
complications.
The overall median survival was 98 days (1-793): 64 (1-104) days after 
gastroduodenal, 98 (7-793) days after esophageal, 127 (6-594) days after biliary and 
140 (8-630) days after colonic stenting. Patients with gastric cancer had the shortest 
survival (median, 54 days), significantly shorter than patients with pancreatic cancer 
(median, 98 days, p=0.001), esophageal cancer (median, 102 days, p=0.005) and colon 
cancer (median, 172 days, p < 0.001).  Patients with longer survival had more 
reinterventions and needed hospital readmissions more frequently. 
In conclusion, long-term outcome after palliative treatment with SEMS for malignant 
GI- and biliary obstruction shows that 70 % had a patent stent until death, and that 
most reobstructions could be solved endoscopically. Hospital readmissions were 
mainly related to progression of the underlying cancer disease. 
Paper 4:
 
Stent treatment of malignant gastric outlet obstruction
- The effect on rate of gastric emptying, symptoms and survival
Gastric emptying rate, symptoms and survival were evaluated in 17 patients with 
malignant gastric outlet obstruction (GOO) treated with duodenal stents.
Following stent treatment, 13 patients (76%) had improved rate of gastric emptying, 
whereas four had unchanged or worsening in rate of empting. There was a significant 
improvement in the symptoms nausea (p=0.046), vomiting (p=0.002) and problems 
swallowing solid food (p=0.007) after treatment.
There was no correlation between survival and gastric emptying or between survival 
and symptoms. 
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In conclusion, treatment with SEMS results in improved gastric emptying in most 
patients with GOO, which corresponds with a reduction in self-reported obstructive 
symptoms. 
Paper 5:
 
Stenting as a bridge to surgery is safe and effective in acute malignant left-sided 
large bowel obstruction 
 
Forty patients with acute malignant obstruction of the left colon (n=26) or rectum 
(n=14) underwent stent treatment as a bridge to surgery (BTS).
Successful stent placement with adequate decompression of the bowel was obtained in 
34 (85%) patients, whereas emergency surgery was necessary in 6 patients, i.e. 15 % 
initial failures. Stent placement failed in two patients and in two patients adequate 
decompression was not achieved despite successful placement of the stent. Two 
patients experienced bowel perforation in relation to the stent procedure. There was no
procedure related mortality.
Tumour resection with primary anastomosis was performed in 32 of the 40 patients 
(70%). Four of the patients with rectal resections with a low anastomosis on the pelvic 
floor level had a routine protective loop ileostomy in an elective setting, and these 
cases were consequently not considered failures.
In conclusion, stenting as bridge to surgery was successful in 77% of the patients who 
then underwent the same surgical procedure, as would have been performed in an 
elective setting.
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General discussion 
Methodological considerations
Patients
Patients were included unselected and consecutively in this observational study. As in 
all non- randomized studies, we can not exclude the risk of selection bias by missed 
inclusions of failed procedures, but the risk is reduced since patients were included 
prospectively. 
Study design
 
The decision to perform a multi-center study was made because palliative treatment 
with SEMS is a decentralized procedure in Norway, and this would make the results 
applicable in everyday clinical practice. This study design also made it possible to 
include the sufficient number of patients within a limited time period, and thereby 
avoid the influence of changes in clinical practice that occurs frequently in this rapidly 
developing field. The disadvantage of a multi-center design was that the inclusion and 
stent procedures were performed by a variety of clinicians in a variety of hospital with 
little control over variations in technique among different hospitals.
RCTs are the gold standard when evaluating new treatment methods. We considered 
the to conduct a RCT comparing the outcomes after emergency surgery to SEMS as 
BTS, but found that it would be very difficult to include the sufficient number of 
patients given the population in Norway. The lack of randomization is a limitation in
the study of colonic SEMS as BTS (paper 5), but the prospective collection of data 
limited the risk of selection bias and the results may add important knowledge.
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Patient reported outcomes
 
Non-responders represent a problem in QoL studies and might influence results in 
both directions137. It has been argued that if the rate of non-responders exceeds 20 %,
it poses a significant risk of bias to the results138. A 100 % response-rate is impossible 
to achieve in a study population like ours. Missing responses have different causes;
hence, the reasons for missing questionnaires must be recorded, in order to evaluate 
the risk of possible selection biases.
We achieved 68 % compliance for completing both QLQs, which is considered 
acceptable in this patient population and in accordance with comparable studies.
Response rates are known to fall with increasing age and as patients come closer to 
death139-142. Seventy-six patients, that had completed QLQ 1, did not return the second 
questionnaire, 27 for unknown reasons.
Figure 6: flow-chart illustrating the selection of the 162 patients included in paper 2.
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This represents a possible risk of selection bias, however, but we know that these 
patients did not differ in age, pre-treatment global health, or survival compared to the 
162 repliers, which reduces the likelihood. Three of the 27 non-responders 
experienced stent dysfunctional and needed re-interventions during the first two weeks, 
which might have influenced their opinion of stent function. We might have 
overestimated the clinical effect of SEMS treatment if patients without the expected 
effect chose not to return the 2nd questionnaire. 
Instruments used in the assessment QoL/PRO must have a high validity, which means 
that they measure what they are supposed to measure, for the purpose of this study:
changes in QoL. If the questions assessed have no relevance to the patients, we will 
not be able to measure and detect changes in the patients QoL.  Our 38- item 
questionnaire was feasible and well functioning for most patients, based on the 
response rate and the low number of missing items. However, 15 patients in a more 
terminal face of their cancer disease declined to complete the QLQ because it was too 
extensive.  The selected organ specific questions turned out to be well suited since the 
majority of patients reported having the assessed symptoms to some degree. The 
exception was the symptom itching that only 50 % of patients with biliary SEMS 
reported before stent treatment.  
To reduce the influence of recall bias, the patients had to complete the initial 
questionnaire no later than the day after the procedure and the second questionnaire no 
later than 3 weeks after treatment.  Sixty-four patients (40%) completed the first 
assessment the day after stent insertion, due to emergency stent treatment or 
pronounced symptoms before treatment.  The scorings from patients who completed 
the pre-treatment questionnaire prior to treatment were similar to patients who 
completed this the day after treatment, but the risk of recall bias can not be eliminated.
The two-week time span between assessments was chosen to reach the maximum 
effect of the stent and reduce the impact of disease progression.  We decided not to 
repeat QoL assessments beyond week two because we primarily wanted to study short 
term outcome of SEMS. We believed that repeated assessment beyond the second 
week not would add further information and that the influence of the progressive 
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cancer disease would make the results difficult to interpret. In retrospect, however, we 
know that repeated assessments would have been possible for many patients and could 
have added important information about long-term outcomes.
Physician reported outcomes
The physicians assessed the same organ specific symptoms as the patients, first at
inclusion and then at hospital discharge or two weeks after stent treatment if the 
patient was still hospitalized. The study protocol did not require a scheduled follow-
up after stent treatment. The patients were often severely ill, with long travelling 
distance to hospital, and an extra hospital visit to allow the physician to perform a 
symptom assessment was hence not included in the follow-up. As the hospital stay 
related to the stent procedure usually was of short duration, the physicians scoring 
often had to be performed at discharge from the hospital.  This led to that the 
physicians’ second assessments were performed earlier than day 7 for 81% of the 
patients while the patients assessed their symptoms between days 7-14. It is difficult to 
predict the possible influence of this discrepancy, but physicians might have 
performed the second assessment before full clinical effect was achieved, and thereby 
underestimated the clinical effect. However, it is likely that the questionnaire’s one 
week time format (symptoms during the last week are assessed) reduced the influence 
of the discrepancy between physicians’ and patients’ second assessment.
Long-term outcomes
Long- term data were collected by a review of the medical journals.  Follow-up visits 
were performed only when needed for the palliatively treated patients since we did not 
want to burden these often severely ill patients with unnecessary hospital visits. The
retrospective collection of data might have led to that minor complications were 
missed, and that the correct complication rate is higher than estimated. It is unlikely 
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that major SEMS complications were overlooked since they would have resulted in 
referral to a public hospital in Norway. The prospectively inclusion of patients 
improves the data quality compared to retrospective materials.
Power calculations were based on detecting clinically significant changes in the 
EORTC C-30 global health score, not on detecting significant differences in 
complications and long-term outcomes. We were able to demonstrate significant
differences for several long-term outcomes, but significant differences might have 
been missed if the included number of patients were too small.
The study population was heterogeneous with regard to cancer type, location of 
obstruction (proximal-distal) and stage of the cancer disease. This might have 
influenced the results, but are in accordance with most comparable literature and
therefore makes the results comparable 74;143-145. Furthermore is it likely SEMS as 
palliative treatment principle can be evaluated independently of cancer type, stage and 
locations for many outcomes.
 
The octanoic acid breath test of gastric emptying 
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Figure 7: Typical example of the gastric emptying breath curve before and after stent 
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Scintigraphy is the gold standard to study gastric emptying 146;147, but for the present 
study, the use of the octanoic breath test was considered more suitable. For patients 
with advanced cancer disease was it fortunate to perform the test in a sitting position in
bed or a comfortable chair, instead in front of a gamma camera. We decided to use a 
gastric emptying test with a solid meal which is more challenging for the stomach to 
grind and empty, than a liquid meal, and therefore more comparable to a normal diet.  
Furthermore, the octanoic breath test is reliable for the study of variation in gastric 
emptying within subjects128. Patients with the most severe symptoms and complete 
obstruction were not included in the study. According to clinical observations, these
patients can expect the best clinical effect of stenting.  We do not know whether this 
has influenced the results, but our patients’ selection might have contributed to a 
underestimation of stent effect on a group level. 
Discussion of results 
Patient reported outcomes
One of this study’s main findings is that the majority of patients reports a significant 
clinical effect on obstructive symptoms and an improved global health score two 
weeks after SEMS treatment (paper 2). These finding correspond with studies by
Madusudhan148 (33 patients were treated with esophageal stents) and van Hooft 149 (52 
patients treated with gastroduodenal stents). Other comparable studies have not been 
able to identify improvement in global health, despite a significant clinical 
improvement in obstructive symptoms 18;19;97;98;150. It is somewhat unexpected that
relief from distressing obstructive symptoms not significantly influences global health
score. Patients with advanced cancer have several health issues that can influence the 
global health score negatively.  A review of the medical charts revealed that absence of 
improvement the scorings often could  be explained by dysfunctional stents, 
migrations, infections, pain, or intercurrent diseases during the first two weeks, but 
these  patients were included in analysis.  Ongoing treatment with other modalities (e.g. 
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chemotherapy) can potentially influence global health negatively, but we found no 
significant difference in scorings for the 25 patients who received chemo- and/or 
radiation therapy during the assessment period. 
Despite that the importance of QoL/PRO measures frequently is emphasized, 
surprisingly few publications have contributed to increased knowledge in this field in 
recent years.  There can be several explanations for this, but most likely is the reasons
that the use of QLQs are time consuming and the results are difficult to interpret 
without special knowledge of the questionnaire used. The mean effect for whole group
of patients is not easily transferred into clinical decision making for each individual 
patient. Several efforts have been made to make the results from QoL studies more 
accessible to clinicians 151-153, and their frequent use in clinical research will increase 
the understanding over time.
Another argument for the incorporation of PROs in clinical studies is that physicians 
and patients evaluate symptoms severity differently, underestimation of patients’ 
symptoms by physicians being more common 87-91;154;155. This trial was the first to 
compare physicians and patients’ assessment of symptoms related to GI-obstruction 
and the clinical effect of SEMS treatment.  We found that physicians reported a 
significantly better treatment effect compared to the patients. The main reason was that 
they evaluated the symptoms before treatment as more pronounced than the patients 
(p< 0.02). We do not know the reasons for the discrepancies in scoring found in the 
present study; but one plausible explanation may reflect the enthusiasm of the 
physicians performing these procedures and their needs to justify the indication. The 
evaluation of clinical outcome in clinical trials should preferably be assessed by PROs 
and a graded scoring by the physicians, since different aspects of the clinical effect is
evaluated. This dual assessment can help anchor the PRO results to clinical changes
that are more familiar to the physicians.
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Long –term outcomes
Short- term outcomes after palliative stent treatment were well documented when we 
planned this study, but publications on long-term outcomes were sparse.  The need for 
repeated, unpleasant procedures and re-hospitalizations will negatively influence the 
QoL of patients with limited life expectancy. Knowledge about clinical outcomes 
measurements beyond the initial technical- and clinical success is hence essential 
when making decisions about palliative treatment options. We evaluated long-term 
outcome for 218 patients palliatively treated for malignant GI-obstructions and found 
that overall 67% had a patent stent without the need of reinterventions their remaining 
life-time (paper 3).  Reobstruction was the most common reason for stent failure 
(80 %), but stent patency could usually be reestablished with a repeated endoscopic 
procedure. There were significant differences in outcomes between locations, and 
factors that might have contributed to this are discussed for each location.
Esophageal stents
Esophageal stents had the highest reintervention rate (41%), which is in accordance 
with previous literature 156-162.  The esophagus is the “first stop” for food passing 
through the GI tract, and food-bolus impaction was the reason for 29 % of the 
reinterventions. Small diameter stents (18 mm) was most commonly used during the 
study period and can in part explain this finding. Larger diameter and covered SEMS 
have been developed and have shown to reduce the risk of reobstruction by food or 
tumor ingrowths145;163;164 , but fully covered stents are encumbered with a high risk of 
migration 49;164.  A partially covered SEMS with medium expansive force, diameter 
20-23 mm may better serve as a basic stent.
Gastroduodenal stents
Patients treated with gastroduodenal stents had significantly shorter survival compared
with the other locations.  The reason was that two-thirds of these patients had 
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advanced gastric (34%) or pancreatic cancer (32%), which often entails short life 
expectancy. There are studies suggesting that surgical GEA should be considered as an 
alternative treatment option for patients with longer life expectancy expected survival, 
due to a lower re-obstruction rate 27;165. The finding, that 75 % of patients with 
gastroduodenal stents did not need any re-intervention, suggests that SEMS was an 
appropriate palliative treatment option for the majority of the patients.
Biliary stents
Biliary SEMS have a longer patency than plastic stents 62 and are usually
recommended for patients with an expected survival of more than three- four 
months 63;166, in order to avoid repeated procedures. Mainly uncovered biliary SEMS 
were used in the present study, and 70% stayed patent during the remaining lifetime of 
the patients which was a median of 128 days. Fifty per cent of patients treated with 
biliary SEMS who were still alive after six months had well functioning stents. This 
demonstrates that the patient selection was appropriate.
Partially covered- and fully covered biliary SEMS have been introduced to further 
prolong patency, but the results have not been unequivocal. Early results were 
promising with regard to increased patency167;168,  but two large RTCs published in 
2010 found  similar re-intervention rates between covered and uncovered biliary 
SEMS 169;170. The initial worries for increased risk of cholecystitis and pancreatitis
have not been confirmed 171. If the problem with migration of covered SEMS can be 
solved they will become first choice treatment for malignant biliary obstruction.
Colonic stents
As patients with advanced colorectal cancer live longer with the help of modern 
multimodal treatment of GI cancer, i.e. chemotherapy, anti-angionetic drugs 
(Bevacizumab) and surgery for metastases, 83;172;173, the number of patients 
experiencing SEMS-related complications, e.g. stent occlusion and perforation of the 
colon expected will increase accordingly 143;174-178. In the present study, long-term
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clinical failure was 33 % for 45 patients palliatively treated with colonic SEMS. This 
is comparable to the failure rates found by Small et al (24 %) 143, Meisner et al 
(32 %) 78 and other authors 74;177;179-181. Fernandez-Esparrach et al 182 reported a 51% 
long-term clinical failure rate, mainly due to migrations and reobstructions. This study,
however, has several weaknesses, as 40 % of the obstructions could be passed with the 
endoscope, and therefore had a questionable indication for stenting and thus a high 
failure rate due to stent migration.
Colonic perforation is a serious complication to SEMS treatment. The clinical 
perforation rate in the present series was 5 %, including one late colonic perforation, 
which is in accordance with comparable literature 143;177;183;184. There was no 
perforation related mortality. A literature review by Datye et al185 evaluated the 
outcome for patients that experienced perforations related to colonic SEMS. The 
mortality directly related to the perforation was 0.8 %, and the overall mortality was 
16.2 %, which is far less than after emergency surgery for colonic obstruction.
The outcomes after palliative colonic stenting are often reported being better for 
primary colonic malignancies than extra- colonic malignancies causing colonic 
obstruction 180;186-188. The reasons are lower technical success rates, higher rates of 
clinical failures and complications.  The study population consisted of only 8/45 
patients with obstructions caused by extra- colonic malignancies, and the outcomes 
were similar to the main study population. According to personal experiences with 
complications after stenting of strictures in patients with carcinomatosis and adherent 
bowel, we have adopted a more reluctant approach to colonic stenting in this group of 
patients.  Our conclusion is nevertheless that palliative treatment with SEMS is a 
better option than palliative surgery if possible. Our conclusion is strengthened by the 
fact that patients in this study were included and treated at small local centers, not 
large expert centers.
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Survival
The overall survival in the present study was three months, which is in line with 
previous publications 5;8;68. Patients with a short life expectancy should not be exposed 
to unnecessary procedures with potential serious complications. Therefore, is an 
estimation of expected survival highly important when making decisions about 
palliative treatment, but can be very difficult 13-15;189-192. In retrospect, we treated and 
included several patients with either very short or very long survival that not were 
optimal candidates for SEMS and should have been treated with a different palliative
option. On the other hand, SEMS treatment was effective palliation to many patients 
with relatively short survival. Our experience is that several of these patients could 
have benefitted from an earlier referral for SEMS treatment. A multidisciplinary 
approach would ensure that palliative cancer patients receive the right palliative 
treatment, at the optimal time.
Gastroduodenal stents effect on gastric emptying
Our initial review (paper 1) reviled that only 24 % of the publications included had 
used objective methods to evaluate the GI- function following stent treatment (oral 
contrast examination), and no studies had performed quantitative tests of gastric 
emptying.
We found that almost 80% of the patients had a significant improvement in the rate of 
gastric emptying and close to 90% reported symptomatic improvement after treatment 
with gastroduodenal stents. The only available previous publication on gastric 
emptying after treatment with gastroduodenal stents is by Meatani et al 110. This study 
used a liquid meal was used to evaluate GE in 14 patients, where 8 patients still had 
delayed gastric emptying after duodenal stent treatment, but the SEMS effect on 
gastric emptying could not be evaluated since no emptying test was performed prior to 
stent treatment.  Interestingly, we found a higher proportion of patients with a normal 
rate of emptying (about 50 %) after treatment, even though we used a solid meal, 
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which is more challenging for the stomach to grind and empty. Maetanis study 
population consisted mainly of patients with gastric cancer while we included mainly 
patients with pancreatic cancer. They used smaller diameter stents (18 mm Ultraflex 
esophageal stents in 50 % of their patients) while we used a stent with 22 mm diameter 
in all our patients, which may have contributed to the difference in outcome. 
Some patients had no symptomatic effect despite a successfully placed and open stent, 
and some patients had a symptomatic effect despite little improvement in GE rate.  In 
addition, there was not always a correlation between the endoscopic findings and GE 
rate. This indicates that other factors are involved in advanced cancer in this location, 
as neurologic infiltration affecting GE
Another aspect we wanted to explore was if a GE test could be a predictor of expected
survival. Jeurninck et al192 had found that the WHO performance score was the only 
significant predictor of survival in patients with malignant gastroduodenal obstruction.
Van Hooft et al 193, that pain on the EORTC C30 scale and the use of opioid analgetics 
were significant predictors of survival in the same group of patients. We were not able 
to detect a relation between survival and gastric emptying, nor were an improved 
gastric emptying rate related to increased survival. Our conclusion is that if a patient 
suffers from GOO, should palliative stent treatment should be considered due to its 
effect on QoL. The gastric emptying test does not add important information that can 
help in clinical decision making.
Colonic stents as a bridge to surgery
The overall mortality rate after emergency surgery for malignant colonic obstructions
is around 20 % 112-114;194-197, and even up to 40 % in patients in ASA class 440. The 
introduction of SEMS as a BTS in the early 1990 was based on encouraging 
publications showing that serious treatment complications and creation of stomas 
could be avoided. 
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In the present series, we were able to achieve tumour resection with primary 
anastomosis in 77 % of the patients. Including 4 patients with rectal resections with a 
low anastomosis on the pelvic floor level, that had a routine protective loop ileostomy
in an elective setting. This was achieved with no procedure related mortality, a clinical
perforation rate of 5 % and an overall complication rate of 16%. Our results are in line 
with multiple reviews10;74;198, observational studies 143;199-202;202-205 and two RCT206;207.
The premises for SEMS as BTS have been challenged by the findings in two recent 
RCT’s comparing SEMS and emergency surgery 208;209 , an observational study 210
and metaanalyses of the available RTCs 211-215. A metanalysis Tan et al211 reported a 
technical- and clinical success rates of 70 % and 69 % in 234 patients treated with
colonic SEMS in an emergency setting. The clinical perforation rate was 7 % and the 
rate of silent perforations was 14 %. Overall did SEMS intervention lead to a higher 
rate of primary anastomosis, but there were no difference in mortality or complications 
between stenting and emergency surgery. A Cochrane review by Sagar 2011212
concluded that the use of stents in malignant colon obstruction had no advantage over 
emergency surgery.
What are the explanations for the unexpected inferior results? Firstly, the technical 
success rates in the two RTCs were unusually low (47% and 70%), which led to very 
low rates of primary anastomosis when intention to treat analysis was performed. The 
technical success rate depends on several factors, such as the endoscopist’s skills, the 
grade of stenosis and the location of the obstructing tumour. Van Hooft et al speculate 
if a higher proportion of complete obstruction (70% - compared to around 50 % in the 
literature) 143;182, explains the high rate of failed procedures in their series. One has to 
speculate if the endoscopists possessed the required experience and skills to perform
this challenging procedure and if the high rate of complications can be related to the 
same issue. Secondly, the fairly high mortality rate in the stent group can be 
influenced by the fact that patients with unsuccessful stent procedures underwent 
emergency surgery. Thirdly, the exclusion of patients with high surgical risk (ASA 4) 
might have lowered the mortality in the emergency surgery group, and thereby offset 
the expected differences between the two groups.
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The role of SEMS as BTS is not resolved as we see it. The discussion whether 
complications to stent placement worsens the oncologic outcome in potentially curable 
patients has been a long on-going, but studies of long-term outcomes and safety are 
still sparse and inconclusive 86;204;214 . Data form observational and retrospective 
studies might be encumbered with selection biases that have led to an overestimation
of the positive effect of SEMS, and the evidence from present RCT’s is limited by
small sample sizes and patients selection. Larger scale studies, preferably RTCs, are 
required to clarify the safety and oncologic long-term outcome of colonic stents as
BTS in obstructing left-sided colorectal cancer. Such trials have proven difficult to 
conduct, which makes data from prospective observational studies valuable, preferably
in the form of treatment registers. Skills in advanced endoscopy are required to use 
SEMS as BTS successfully in an emergency setting, and thereby achieve the treatment 
goals which are primary anastomosis and a low rate of complications. Each physician 
will have to determine if they have the sufficient skills when considering SEMS as 
BTS in young potentially curable patients.
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Conclusions
 
x A literature review revealed that available reports regarding the clinical 
outcome of treatment with gastroduodenal stents were insufficient. Relevant 
information of the clinical outcome was lacking, and few studies had utilized
objective parameters to evaluate outcome and no studies had assessed PRO.  
 
x Patients evaluate treatment with SEMS as effective in relieving symptoms 
related to malignant GI-obstruction.  SEMS as palliative principle seems to be 
effective independently of location.  Our conclusion is strengthened by the fact 
that patients in this study were included and treated at small local centers, not 
large expert centers.
x The present study demonstrates a significant difference in how the physicians 
and patients evaluate treatment effects and thereby emphasizes the importance 
of taking patient reported outcomes into account when evaluating clinical 
palliative interventions. 
x Long-term outcomes demonstrated that palliative treatment with SEMS was 
safe and that 70 % of the patients did not need any reintervention for 
obstructive symptoms. Reobstruction was the reason for 80 % of the stent 
failures, but could usually be solved with a repeated endoscopic procedure.
There are significant differences in patency and survival between the four stent 
locations. The prevalence of serious adverse events for all stent localizations 
was low.
x Almost 80% of the patients treated with gastroduodenal stents had a significant 
improvement in the rate of gastric emptying. This indicates that if a patient 
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suffers from GOO, palliative stent treatment should be considered. The 
improved rate of emptying does not seem to have effect on survival.
x Treatment with colonic stents as bridge to surgery was safe in patients with left-
sided large bowel obstruction; there was no procedure related mortality and few 
serious complications. Stenting was effective in avoiding the use of a diverting 
stoma. 
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Clinical implications 
This study confirms that palliative treatment with SEMS represents a safe and 
effective treatment for most patients with malignant GI- and biliary obstruction. It can 
be expected that around 70 % will have a patent stent until death, and that if
reobstructions occurs, can this be could solved with a repeated endoscopic procedure.
This study confirms that the treatment can be performed with good results in a 
decentralized manner, as in Norway.
Patients and physicians can evaluate the severity of symptoms differently. The use of 
PRO adds important information about treatment outcome in clinical trials, but can 
also be used everyday clinical practice to identify and priorities the patients’ problems 
before a consultation, and improve the delivery of palliative care.
BTS can be performed safely in the majority of patients with left-sided colonic cancer 
and effectively prevent stomas, but skills in advanced endoscopy are required to 
achieve a technical success rate and avoid serious complications. It is unresolved 
whether SEMS as BTS adversely affects oncologic in patients treated with curative
intent. The potential risks emergency surgery and stents have to be weighed against 
each other for every individual patient.
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Future perspectives
Palliative stenting of malignant gastrointestinal obstruction is considered a safe and 
effective treatment option for most patients, but there are issues that need further 
investigation and clarification.
Further development of covered SEMS anti- migration properties is important.  
Increased knowledge about the optimal balance between stents diameter, length, 
radial- and expansive forces will improve clinical success rates and reduce the rate of 
complications.  There seems to be an association between esophageal SEMS, radiation 
therapy and increased risk of esophago-tracheal fistulas, but results from clinical trails 
are divergent. It seems like the timing of the two treatment modalities are important, 
and this requires further investigation. Prospective randomized trials would be the gold 
standard to clarify these issues, but it has proven difficult to include the sufficient 
number of patients to be able to draw conclusions. 
The establishment of a national SEMS register could be a possible way to collect data 
large enough to clarify unanswered questions and develop national treatment 
guidelines. The Cancer Registry of Norway possesses detailed information about the 
cancer prevalence in Norway. Combined data from this two registers would provide 
important information about SEMS prevalence’s and differences between health 
regions
There use of SEMS as BTS in patients with curative colonic cancer has been under 
reevaluation in recent years. Theoretically SEMS related complications can lead to 
tumor dissemination and unfavourable oncologic outcome in potentially curable 
patients. Our opinion is that RCTs are encumbered to many weaknesses to draw final 
conclusions about the use of SEMS as BTS and further investigations are needed.  It is 
unlikely that RTCs good and large enough to settle these issues it will be conducted
and therefore are prospective data from treatment registers important.
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Erratum
Paper 3 page 1509: Survival gastroduodenal stents, corrected from 64 (1-113) to 64 (1-
413).
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Appendices
 
 
 
 
 
Pasientinformasjon og forespørsel om deltagelse i en undersøkelse: 
 
Bruk av stenter ved kreft i mage-tarmkanalen 
 
 
Hensikt med undersøkelsen 
Ved kreft i mage-tarmkanalen vil kreftsvulsten etter hvert kunne lage et passasjehinder som gir forskjellige 
plager avhengig av hvor svulsten sitter. Du vil få behandling for dette med en selvekspanderende 
metallstent (SEMS) . Dette er et nettingrør av metall som legges inn ved hjelp av instrumenter som brukes 
ved endoskopisk undersøkelse. Røret vil legges igjennom svulsten og lage en åpning som vil lindre plagene 
som skyldes trang passasje. 
Innlegging av SEMS er et nytt behandlingsprinsipp som har vist seg å være et godt og trygt alternativ til 
kirurgi. Komplikasjoner er sjelden, og vanligvis ikke alvorlige. Bruken og effekten av innleggelse av SEMS 
er imidlertid ikke tilstrekkelig studert. Denne undersøkelsen har derfor som formål å studere bruken og 
nytten av behandlingen.  
 
For å gjennomføre undersøkelsen ønsker man å registrere opplysninger knyttet til alle innleggelser av 
SEMS i Osloregionen i løpet av en 2 års periode. Hos en utvalgt gruppe pasienter vil man spesielt 
kartlegge effekten av behandlingen med tanke på hvordan pasientene selv opplever nytten av denne. 
 
 
Konsekvenser for deg 
Dersom du velger å delta i undersøkelsen betyr dette i første omgang at du vil bli bedt om å svare på noen 
spørsmål angående plagene dine forut for behandlingen. Ved hjemreise fra sykehuset vil du få med deg et 
skjema med spørsmål som du skal svare på 2 uker etter behandlingen og som deretter sendes tilbake til oss 
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i posten. I tillegg vil vi registrere en del data rundt selve behandlingen du får. Disse dataene hentes fra din 
journal.  
 
Opplysningene vil bli lagret i ett avidentifisert register ved Ullevål universitetssykehus. Et prosjektnummer 
knytter deg som person til prosjektet gjennom en navneliste. Kun prosjektansvarlig har adgang til 
navnelisten. Etter at undersøkelsen er avsluttet og resultatene er ferdig analysert vil navnelisten slettes, 
senest i juni 2011. Alle opplysningene i denne undersøkelsen vil bli behandlet konfidensielt. Personvernet 
ivaretas i samsvar med betingelser gitt i melding til personvernombudet ved Ullevål sykehus. 
 
 
Dine rettigheter 
Det er helt frivillig å delta i undersøkelsen. Du kan når som helst be om innsyn eller trekke deg fra 
registeret uten at du må gi noen forklaring. Du har rett til å få korrigert eventuelle feil i de opplysningene 
vi har registrert. Hvis du på et senere tidspunkt velger å trekke deg fra studien, kan du kreve at 
opplysninger om deg slettes. Ved henvendelse til prosjektansvarlig kan du få nærmere opplysninger om 
dette. 
 
Denne undersøkelsen er kun en registrering og om du velger å ikke delta i studien vil dette ikke få 
konsekvenser for den behandlingen du får. Ditt bidrag er imidlertid viktig for at vi skal kunne gi pasienter 
best mulig behandling.  
 
Regional komité for medisinsk forskningsetikk, Øst-Norge har vurdert prosjektet, og har ingen 
innvendinger mot at dette gjennomføres.  
 
Prosjektansvarlig/Mer informasjon 
Hvis du har spørsmål om studien, kan du kontakte din lege eller prosjektansvarlig: 
Dr.Lene Larssen, gastromedisinsk avdeling Ullevål universitetssykehus.Tlf.93041073/22119100, e-post: 
lene.larssen@ulleval.no eller lene.larssen@medisin.uio.no 
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EORTC QLQ-C30 (version 3.0.)
Vi er interessert i forhold vedrørende deg og din helse. Vær så vennlig å besvare hvert spørsmål ved å sette
en ring rundt det tallet som best beskriver din tilstand. Det er ingen "riktige" eller "gale" svar. Alle 
opplysningene vil bli behandlet konfidensielt.
1. Har du vanskeligheter med å utføre anstrengende
Ikke i det
hele tatt Litt Endel
Svært
mye
aktiviteter, slik som å bære en tung handlekurv
eller en koffert? 1 2 3 4
2. Har du vanskeligheter med å gå en lang tur? 1 2 3 4
3. Har du vanskeligheter med å gå en kort tur utendørs? 1 2 3 4
4. Er du nødt til å ligge til sengs eller sitte i en stol
i løpet av dagen? 1 2 3 4
5. Trenger du hjelp til å spise, kle på deg, vaske deg
eller gå på toalettet? 1 2 3 4
I løpet av den siste uka: Ikke i det
hele tatt Litt Endel
Svært
mye
6. Har du hatt redusert evne til å arbeide eller
utføre andre daglige aktiviteter? 1 2 3 4
7. Har du hatt redusert evne til å utføre dine 
hobbyer eller andre fritidsaktiviteter? 1 2 3 4
8. Har du vært tung i pusten? 1 2 3 4
9. Har du hatt smerter? 1 2 3 4
10. Har du hatt behov for å hvile? 1 2 3 4
11. Har du hatt søvnproblemer? 1 2 3 4
12. Har du følt deg slapp? 1 2 3 4
13. Har du hatt dårlig matlyst? 1 2 3 4
14. Har du vært kvalm? 1 2 3 4
Bla om til neste side
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I løpet av den siste uka: Ikke i det
hele tatt Litt Endel
Svært
mye
15. Har du kastet opp? 1 2 3 4
16. Har du hatt treg mage? 1 2 3 4
17. Har du hatt løs mage? 1 2 3 4
18. Har du følt deg trett? 1 2 3 4
19. Har smerter påvirket dine daglige aktiviteter? 1 2 3 4
20. Har du hatt problemer med å konsentrere deg,
f.eks. med å lese en avis eller se på TV? 1 2 3 4
21. Har du følt deg anspent? 1 2 3 4
22. Har du vært engstelig? 1 2 3 4
23. Har du følt deg irritabel? 1 2 3 4
24. Har du følt deg deprimert? 1 2 3 4
25. Har du hatt problemer med å huske ting? 1 2 3 4
26. Har din fysiske tilstand eller medisinske behandling 
påvirket ditt familieliv? 1 2 3 4
27. Har din fysiske tilstand eller medisinske behandling 
påvirket dine sosiale aktiviteter? 1 2 3 4
28. Har din fysiske tilstand eller medisinske behandling 
gitt deg økonomiske problemer? 1 2 3 4
Som svar på de neste spørsmålene sett en ring rundt det tallet fra 1 til 7
som best beskriver din tilstand
29.  Hvordan har din helse vært i løpet av den siste uka?
1 2 3 4 5 6 7
Svært dårlig Helt utmerket
30. Hvordan har livskvaliteten din vært i løpet av den siste uka?
1 2 3 4 5 6 7
Svært dårlig Helt utmerket
 
Endel pasienter opplever av og til at de har noen av følgende symptomer eller problemer. Vær 
vennlig å angi i hvilken grad du har hatt disse symptomene eller problemene i løpet av den siste 
uka. Sett en ring rundt det tallet som best beskriver din tilstand. 
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I løpet av den siste uka: Ikke I det   Svært 
  hele tatt Litt Endel mye 
31. Har du hatt problemer med å innta fast føde? 1 2 3 4 
32. Har du hatt problemer med å innta moset eller bløt føde? 1 2 3 4 
33. Har du hatt problemer med å innta væske? 1 2 3 4 
34. Har du følt ubehag ved spising? 1 2 3 4 
35. I hvilken grad har huden din vært gul? 1 2 3 4 
36. Har du hatt kløe? 1 2 3 4 
37. Har du hatt magesmerter? 1 2 3 4 
38. Har du hatt oppblåst mage? 1 2 3 4 
 
 
 
 
 
 
Sendes til: Dr.Lene Larssen, gastromed.avd.Ullevål Universitetssykehus 
        Kirkeveien 144, 0407 Oslo. Ved spørsmål ring: 93041073 
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Abstract
Background: Malignant gastric outlet obstruction (GOO) is commonly seen in patients with
advanced gastric-, pancreatic-, duodenal, hepatobiliary or metastatic malignancies. Ten to 25% of
patients with pancreatic cancer will develop duodenal obstruction during the course of the disease.
Duodenal stenting with self-expandable metal stents is an alternative treatment to surgical bypass
procedures. Our aim was to review the published literature regarding treatment of malignant GOO
with stents to reveal whether the information provided is sufficient to evaluate the clinical effects
of this treatment
Methods: A literature search from 2000 – 2007 was conducted in Pub Med, Embase, and
Cochrane library, combining the following search terms: duodenal stent, malignant duodenal
obstruction, gastric outlet obstruction, SEMS, and gastroenteroanastomosis.
All publications presenting data with t 15 patients and only articles written in English were included
and a review focusing on the following parameters were conducted: 1) The use of graded scoring
systems evaluating clinical success; 2) Assessment of Quality of life (QoL) before and after
treatment; 3) Information on stent-patency; 4) The use of objective criteria to evaluate the stent
effect.
Results: 41 original papers in English were found; no RCT's. 16 out of 41 studies used some sort
of graded scoring system. No studies had objectively evaluated QoL before or after stent
treatment, using standardized QoL-questionnaires, 32/41 studies reported on stent patency and 9/
41 performed an oral contrast examination after stent placement. Objective quantitative tests of
gastric emptying had not been performed.
Conclusion: Available reports do not provide sufficient relevant information of the clinical
outcome of duodenal stenting. In future studies, these relevant issues should be addressed to allow
improved evaluation of the effect of stent treatment.
Background
Malignant gastric outlet obstruction (GOO) is commonly
seen in patients with advanced gastric-, pancreatic-, duo-
denal, hepatobiliary or metastatic malignancies. Ten to
25% of patients with pancreatic cancer will develop duo-
denal obstruction during the course of the disease [1,2].
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GOO may result in nausea and vomiting, leading to dehy-
dration and cachexia, which severely reduces the patients'
Quality of Life (QoL).
Traditionally, a surgical by-pass procedure, usually a gas-
trojejunoanastomosis (GEA), has been the palliative treat-
ment offered, but up to 31% of the patients do not
experience sufficient symptom relief following GEA [1,3].
Furthermore, GEA has a peri-operative morbidity as high
as 35% and a mortality rate of about 2% in later studies
[1,4-7].
Duodenal stenting with self-expandable metal stents
(SEMS) is an alternative treatment to surgical bypass pro-
cedures. In several studies, this treatment has been evalu-
ated as safe and efficient with a technical success rate of
90–100%, a clinical success rate of 67–100%, a rate of
severe complications about 7% and non-severe complica-
tion rate about 20% [2,6-8,8-47]. Compared with surgery,
the patients treated with stents have fewer serious compli-
cations and less need for intensive care unit (ICU) [5] Fur-
thermore, the hospital stay is shorter, which is essential in
palliative treatment [5,9,20,32,7].
In palliative cancer treatment, improvement of QoL is a
primary goal and needs to be addressed when new treat-
ment strategies and procedures are implemented and eval-
uated. Relief from obstructive symptoms is the most
important parameter for evaluating the clinical effect or
treatment outcome following duodenal stenting of GOO,
but complications, stent patency and need for re-interven-
tions are also parameters influencing QoL. In the availa-
ble reports, objective criteria of treatment effects are often
missing, which make it difficult to compare results and
draw conclusions concerning effects of the treatment
offered.
To review the published literature regarding treatment of
malignant GOO with stents to reveal whether the infor-
mation provided is sufficient to evaluate the clinical
effects of this treatment, and whether QoL has been
assessed.
Methods
A search for published literature for the time period Janu-
ary 2000 – September 2007 was conducted in Pub Med,
Embase, and Cochrane library, combining the following
search terms: duodenal stent, malignant duodenal
obstruction, gastric outlet obstruction, SEMS, and gastro-
enteroanastomosis. Reference lists were hand-searched
for additional literature. Furthermore, reference lists of
review articles and metaanalyses from the relevant time
period were used to identify additional literature.
Abstracts were not included. Only studies presenting data
with t 15 patients and only articles written in English
were included in the present review. When studies
included identical patients, the most recent study was
included.(see additional file 1)
The identified studies were reviewed with regard to the
following parameters:
1. The use of a graded scoring systems evaluating clinical
success
2. Assessment of QoL before and after treatment
3. Information on stent-patency
Stent patency defined as the time period without need for
re-intervention
4. The use of objective criteria to evaluate the stent effect
Results
When applying the search criteria, 41 original papers and
four review articles in English were found (See table 1).
The number of patients included in the original papers
was 15–213. Of the studies using a combined endoscopic/
fluoroscopic method for stent placement ten were pro-
spective and 18 retrospective, corresponding numbers for
the studies in which only fluoroscopy was applied were 10
and three, respectively. All prospective and retrospective
studies are listed in table 2 and 3 respectively. No rand-
omized controlled trials (RTC's) treating t 15 patients
with stents were found.
Clinical effect and scoring systems
To evaluate the clinical effects of stent treatment, 16 out of
41 studies used some sort of graded scoring system (see
table 4). The level of oral intake before and after stent
treatment was divided into four to five levels, which
Table 1: Characteristics of studies included in the review (n = 41)
Characteristics n (% of total)
Prospective studies 20 (49%)
Retrospective studies 21 (51%)
Stent deployed by fluoroscopic guidance 13 (32%)
Stent deployed by combined endoscopic/fluoroscopic guidance 28 (68%)
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allows some comparison of the results. The scoring sys-
tems used are adapted from studies on dysphagia in
esophageal cancer. One of the most frequently used is
Gastric Outlet Obstruction Scoring System (GOOSS) pre-
sented by Adler in 2002 [2] (0 = no/inadequate oral
intake, 1 = liquids/thickened liquids, 2 = semisolids/low
residue diet, 3 = unmodified diet). This system assigns a
point score based on the level of oral intake. Song et al
[48] introduced another similar scoring system (0 = able
to eat normal diet, 1 = able to tolerate fragmented solid
food without vomiting, 2 = able to tolerate soft food with-
out vomiting, 3 = able to tolerate only liquid diet without
vomiting, 4 = not able to tolerate any oral intake without
vomiting, 5 = vomiting even without oral intake), mostly
used in radiological literature, in which vomiting as an
important symptom of obstruction is included. The
GOOSS score was applied by 6/41 studies, 1/41 applied
the Song score and 8/41 used similar graded scores. Fur-
thermore, in 2007 Lowe et al introduced a Gut function
score (0 = profuse vomiting or gut not functioning, 1 =
nausea and occasional vomiting, 2 = nausea only, 3 = nor-
mal gut function). This function score is used in addition
to GOOSS and grades the level of nausea and vomiting. At
present, the Gut Function Score has only been applied in
the study, in which it was originally presented [44].
QoL in the evaluation of clinical success
No studies had objectively evaluated QoL before or after
stent treatment, using standardized QoL-forms (see table
4). Seven of 41 studies used the Karnofsky performance
scale before and after stent treatment (A physical perform-
ance scale from 100-0, where a scoring of 100 is normal
function and 0 is dead).
Stent patency
Concerning stent patency, 32/41 studies reported on this
variable (see table 4), either by reporting the exact number
of stent failures and time to failure after stent deployment
or by calculating the patency. The rate of re-obstruction
was reported in 36/41 studies, the migration rate in 34/41
studies.
Objective criteria for stent function
An oral contrast examination was performed after stent
placement in 9/41 studies (see table 4). Objective quanti-
tative tests of gastric emptying before and after treatment
were not performed in any of the evaluated studies.
Discussion
The present review demonstrates that a graded scoring sys-
tem for symptom assessment was used in 40% of the eval-
uated papers. No studies provided information on QoL,
although 17% of the studies used the Karnofsky scale.
Table 2: Prospective studies
Author Year Patients (n)
Jung (16) 2000 19
Lopera (11) 2001 16
Pabon (12) 2001 29
J.H. Kim (13) 2001 29
Park (14) 2001 24
Jung (17) 2002 39
Lee(21) 2003 17
Tang (22) 2003 21
Nassif (23) 2003 63
Holt (26) 2004 28
Jeong (27) 2004 25
Johnsson (5) 2004 21
Hayashi (47) 2005 31
Yoon (35) 2006 82
Espinel (36) 2006 24
Song (42) 2007 20
Mutignani(43) 2007 64
J.H Kim (41) 2007 213
Lowe(44) 2007 87
Maetani (45) 2007 37
Table 3: Retrospective studies
Author Year Patients (n)
Yim (9) 2001 29
Razzaq (10) 2001 23
Aviv (18) 2002 15
Maetani (15) 2002 23
Adler (2) 2002 36
M. Kaw (19) 2003 18
Mittal (6) 2003 16
Stawawy (20) 2003 24
G.H. Kim (24) 2004 49
Lindsay (25) 2004 40
Telford (29) 2004 176
Mosler (30) 2005 36
Bessoud (32) 2005 72
Del Piano (31) 2005 24
Maetani (7) 2005 22
Maire (33) 2006 24
Kazi (34) 2006 23
Kiely (37) 2007 30
T.O. Kim (40) 2007 53
J. van Hooft (38) 2007 62
Jeurnink (8) 2007 53
Table 4: Evaluation criteria applied in the reviewed studies 
(n = 41)
Evaluation criteria n (% of total)
Quality of Life assessment 0
Objective criteria for stent function 9 (22%)
Clinical effect by graded scoring 15 (37%)
Stent patency 33 (80%)
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Information on stent patency was given in 80% of the
studies and 22% had performed oral contrast examina-
tion following stent placement to objectify the stent effect.
No studies quantified the effect of stent placement on rate
of gastric emptying.
The main complaints of patients suffering from malignant
duodenal obstruction are often nausea, severe vomiting,
bloating and abdominal pain. It is questionable whether
the applied scoring systems in the papers reviewed pro-
vide adequate and sufficient information about relief
from these symptoms after stent placement. Improvement
of symptoms estimated by a dysphagia score provides lim-
ited information concerning the effect of duodenal stent-
ing, and should thus be used in combination with a
scoring system providing information about the more
characteristic symptoms of GOO. The Gut Function Score
may be a step in the right direction [44], but this scoring
system needs further evaluation and validation.
In the present review, no studies were identified using
standardized forms to assess QoL before and after stent
treatment. One randomized study used SF-36 to evaluate
the QoL in 10 patients treated with duodenal stents [49],
which is a validated and frequently used QoL question-
naire. This study was, however, too small for inclusion in
this review. In 16% of the studies, the Karnofsky scale was
used, but this scale captures only one aspect of QoL (phys-
ical function) and is today considered inadequate for eval-
uation of QoL [51]. Also for surgical treatment of GOO,
data on the effect of QoL is limited [3]. There have been
developed and validated several complex and advanced
questionnaires for specific symptoms and specific diseases
for the assessment of QoL [51]. EORTC C30 and the organ
specific modules are now widely used for the evaluation
of palliative cancer treatment. By applying these validated
tools, the information about the QoL of patients is
improved, and a possible discrepancy between the QoL of
the patient estimated by the physician and the patient
might be revealed. Studies regarding QoL in palliative
cancer treatment have shown that physicians tend to over-
estimate improvement in QoL of the patients [52,53].
Stent-patency related to survival is an important parameter,
because the need for re-interventions and re-hospitaliza-
tions most likely will reduce the patients QoL. Re-obstruc-
tion of the stent by tumor in- and overgrowth is known to
occur in 15–20% of the patients [28] and is probably the
most important factor influencing stent patency.
The main effect of stent treatment in GOO is re-establish-
ing the passage of food from the stomach to the duode-
num. Evaluation of the stent effect can hence be provided
by measuring the rate of gastric empting before and after
stent placement. None of the reviewed studies included
information on this issue. In a recent study by Maetani et
al, delayed gastric emptying of a liquid meal after stent
placement was demonstrated. The patients resumed oral
intake after stenting and those with a severe delay of emp-
tying had a reduced survival time [54]. Rate of gastric
emptying was, however, only recorded after stenting, and
the quantitative effect of stenting was thus not revealed.
More detailed data on the effect of stenting on rate of gas-
tric emptying is thus required, and can be used to improve
the knowledge on the relation between GOO and obstruc-
tive symptoms. This is an important issue, since the rela-
tion between gastrointestinal symptoms and gastric
emptying might be rather weak [55]. Furthermore, knowl-
edge concerning the effect of SEMS on gastric emptying
could possibly help identifying subgroups of patients, in
which stenting is particularly beneficial. Gastric emptying
is a complex process involving grinding and emptying of
the meal, and it is not likely that the re-establishment of
passage is followed by a more rapid rate of gastric empty-
ing in all subjects treated.
Conclusion
Only 40% of the studies reviewed used a graded scoring
system to evaluate the clinical effect of their treatment.
Furthermore, most studies using a graded scoring system
applied a point score adapted from dysphagia in esopha-
geal cancer and did thereby not address the symptoms
more specific for GOO. The presence of obstructive symp-
toms (severe vomiting, nausea and bloating) is probably
severely reducing the patients QoL. In palliative cancer
care, improvement of QoL is a main treatment goal, and
data on this issue are missing in all the evaluated papers.
Objective evaluation of gastric/duodenal function after
stenting is limited and no studies have performed quanti-
tative tests of gastric emptying. The present review thus
indicates that the available reports do not provide suffi-
cient relevant information of the clinical outcome of duo-
denal stenting. In future studies, these relevant issues
should be addressed to allow improved evaluation of the
effect of stent treatment.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LL performed the systematic search and drafted the man-
uscript in cooperation with AWM and TH. All three
authors have read and approved the final manuscript.
Additional material
Additional file 1
supplementary file including all details concerning the search.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
230X-9-45-S1.doc]
BMC Gastroenterology 2009, 9:45 http://www.biomedcentral.com/1471-230X/9/45
Page 5 of 6
(page number not for citation purposes)
References
1. Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Cole-
man J, et al.: Is prophylactic gastrojejunostomy indicated for
unresectable periampullary cancer? A prospective rand-
omized trial.  Ann Surg 1999, 230:322-328.
2. Adler DG, Baron TH: Endoscopic palliation of malignant gas-
tric outlet obstruction using self-expanding metal stents:
experience in 36 patients Systematic review of the efficacy
and safety of colorectal stents.  Am J Gastroenterol 2002, 97:72-78.
3. Van Heek NT, De Castro SM, van Eijck CH, van Geenen RC, Hes-
selink EJ, Breslau PJ, et al.: The need for a prophylactic gastroje-
junostomy for unresectable periampullary cancer: a
prospective randomized multicenter trial with special focus
on assessment of quality of life.  Ann Surg 2003, 238:894-902.
4. Choi YB: Laparoscopic gatrojejunostomy for palliation of gas-
tric outlet obstruction in unresectable gastric cancer.  Surg
Endosc 2002, 16:1620-1626.
5. Johnsson E, Thune A, Liedman B: Palliation of malignant gas-
troduodenal obstruction with open surgical bypass or endo-
scopic stenting: clinical outcome and health economic
evaluation.  World J Surg 2004, 28:812-817.
6. Mittal A, Windsor J, Woodfield J, Casey P, Lane M: Matched study
of three methods for palliation of malignant pyloroduodenal
obstruction.  Br J Surg 2004, 91:205-209.
7. Maetani I, Akatsuka S, Ikeda M, Tada T, Ukita T, Nakamura Y, et al.:
Self-expandable metallic stent placement for palliation in
gastric outlet obstructions caused by gastric cancer: a com-
parison with surgical gastrojejunostomy.  J Gastroenterol 2005,
40:932-937.
8. Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD:
Stent versus gastrojejunostomy for the palliation of gastric
outlet obstruction: a systematic review.  BMC Gastroenterol
2007, 7:18.
9. Yim HB, Jacobson BC, Saltzman JR, Johannes RS, Bounds BC, Lee JH,
et al.: Clinical outcome of the use of enteral stents for pallia-
tion of patients with malignant upper GI obstruction.  Gas-
trointest Endosc 2001, 53:329-332.
10. Razzaq R, Laasch HU, England R, Marriott A, Martin D: Expandable
metal stents for the palliation of malignant gastroduodenal
obstruction.  Cardiovasc Intervent Radiol 2001, 24:313-318.
11. Lopera JE, Alvarez O, Castano R, Castaneda-Zuniga W: Initial expe-
rience with Song's covered duodenal stent in the treatment
of malignant gastroduodenal obstruction.  J Vasc Interv Radiol
2001, 12:1297-1303.
12. Pinto PI, Diaz LP, Ruiz De Adana JC, Lopez HJ: Gastric and duode-
nal stents: follow-up and complications.  Cardiovasc Intervent
Radiol 2001, 24:147-153.
13. Kim JH, Yoo BM, Lee KJ, Hahm KB, Cho SW, Park JJ, et al.: Self-
expanding coil stent with a long delivery system for palliation
of unresectable malignant gastric outlet obstruction: a pro-
spective study.  Endoscopy 2001, 33:838-842.
14. Park KB, Do YS, Kang WK, Choo SW, Han YH, Suh SW, et al.: Malig-
nant obstruction of gastric outlet and duodenum: palliation
with flexible covered metallic stents.  Radiology 2001,
219:679-683.
15. Maetani I, Tada T, Shimura J, Ukita T, Inoue H, Igarashi Y, et al.: Tech-
nical modifications and strategies for stenting gastric outlet
strictures using esophageal endoprostheses.  Endoscopy 2002,
34:402-406.
16. Jung GS, Song HY, Kang SG, Huh JD, Park SJ, Koo JY, et al.: Malignant
gastroduodenal obstructions: treatment by means of a cov-
ered expandable metallic stent-initial experience.  Radiology
2000, 216:758-763.
17. Jung GS, Song HY, Seo TS, Park SJ, Koo JY, Huh JD, et al.: Malignant
gastric outlet obstructions: treatment by means of coaxial
placement of uncovered and covered expandable nitinol
stents.  J Vasc Interv Radiol 2002, 13:275-283.
18. Aviv RI, Shyamalan G, Khan FH, Watkinson AF, Tibballs J, Caplin M,
et al.: Use of stents in the palliative treatment of malignant
gastric outlet and duodenal obstruction.  Clin Radiol 2002,
57:587-592.
19. Kaw M, Singh S, Gagneja H: Clinical outcome of simultaneous
self-expandable metal stents for palliation of malignant bil-
iary and duodenal obstruction.  Surg Endosc 2003, 17:457-461.
20. Stawowy M, Kruse A, Mortensen FV, Funch-Jensen P: Endoscopic
stenting for malignant gastric outlet obstruction.  Surg Lapar-
osc Endosc Percutan Tech 2007, 17:5-9.
21. Lee DW, Chan AC, Ng EK, Wong SK, Lau JY, Chung SC: Through-
the-scope stent for malignant gastric outlet obstruction.
Hong Kong Med J 2003, 9:48-50.
22. Tang T, Allison M, Dunkley I, Roberts P, Dickinson R: Enteral stent-
ing in 21 patients with malignant gastroduodenal obstruc-
tion.  J R Soc Med 2003, 96:494-496.
23. Nassif T, Prat F, Meduri B, Fritsch J, Choury AD, Dumont JL, et al.:
Endoscopic palliation of malignant gastric outlet obstruction
using self-expandable metallic stents: results of a multi-
center study.  Endoscopy 2003, 35:483-489.
24. Kim GH, Kang DH, Lee DH, Heo J, Song GA, Cho M, et al.: Which
types of stent, uncovered or covered, should be used in gas-
tric outlet obstructions?  Scand J Gastroenterol 2004,
39:1010-1014.
25. Lindsay JO, Andreyev HJ, Vlavianos P, Westaby D: Self-expanding
metal stents for the palliation of malignant gastroduodenal
obstruction in patients unsuitable for surgical bypass.  Aliment
Pharmacol Ther 2004, 19:901-905.
26. Holt AP, Patel M, Ahmed MM: Palliation of patients with malig-
nant gastroduodenal obstruction with self-expanding metal-
lic stents: the treatment of choice?  Gastrointest Endosc 2004,
60:1010-1017.
27. Jeong JY, Kim YJ, Han JK, Lee JM, Lee KH, Choi BI, et al.: Palliation
of anastomotic obstructions in recurrent gastric carcinoma
with the use of covered metallic stents: clinical results in 25
patients.  Surgery 2004, 135:171-177.
28. Dormann A, Meisner S, Verin N, Wenk LA: Self-expanding metal
stents for gastroduodenal malignancies: systematic review
of their clinical effectiveness.  Endoscopy 2004, 36:543-550.
29. Telford JJ, Carr-Locke DL, Baron TH, Tringali A, Parsons WG, Gab-
brielli A, et al.: Palliation of patients with malignant gastric out-
let obstruction with the enteral Wallstent: outcomes from a
multicenter study.  Gastrointest Endosc 2004, 60:916-920.
30. Mosler P, Mergener KD, Brandabur JJ, Schembre DB, Kozarek RA:
Palliation of gastric outlet obstruction and proximal small
bowel obstruction with self-expandable metal stents: a single
center series.  J Clin Gastroenterol 2005, 39:124-128.
31. Del PM, Ballare M, Montino F, Todesco A, Orsello M, Magnani C, et
al.: Endoscopy or surgery for malignant GI outlet obstruc-
tion?  Gastrointest Endosc 2005, 61:421-426.
32. Bessoud B, de BT, Denys A, Kuoch V, Ducreux M, Precetti S, et al.:
Malignant gastroduodenal obstruction: palliation with self-
expanding metallic stents.  J Vasc Interv Radiol 2005, 16:247-253.
33. Maire F, Hammel P, Ponsot P, Aubert A, O'Toole D, Hentic O, et al.:
Long-term outcome of biliary and duodenal stents in pallia-
tive treatment of patients with unresectable adenocarci-
noma of the head of pancreas.  Am J Gastroenterol 2006,
101:735-742.
34. Kazi HA, O'Reilly DA, Satchidanand RY, Zeiderman MR: Endoscopic
stent insertion for the palliation of malignant gastric outlet
obstruction.  Dig Surg 2006, 23:28-31.
35. Yoon CJ, Song HY, Shin JH, Bae JI, Jung GS, Kichikawa K, et al.: Malig-
nant duodenal obstructions: palliative treatment using self-
expandable nitinol stents.  J Vasc Interv Radiol 2006, 17:319-326.
36. Espinel J, Sanz O, Vivas S, Jorquera F, Munoz F, Olcoz JL, et al.: Malig-
nant gastrointestinal obstruction: endoscopic stenting ver-
sus surgical palliation.  Surg Endosc 2006, 20:1083-1087.
37. Kiely JM, Dua KS, Graewin SJ, Nakeeb A, Erickson BA, Ritch PS, et al.:
Palliative stenting for late malignant gastric outlet obstruc-
tion.  J Gastrointest Surg 2007, 11:107-113.
38. van HJ, Mutignani M, Repici A, Messmann H, Neuhaus H, Fockens P:
First data on the palliative treatment of patients with malig-
nant gastric outlet obstruction using the WallFlex enteral
stent: a retrospective multicenter study.  Endoscopy 2007,
39:434-439.
39. Jeurnink SM, Steyerberg EW, Hof GV, van Eijck CH, Kuipers EJ,
Siersema PD: Gastrojejunostomy versus stent placement in
patients with malignant gastric outlet obstruction: a com-
parison in 95 patients.  J Surg Oncol 2007, 96(5):389-96.
40. Kim TO, Kang DH, Kim GH, Heo J, Song GA, Cho M, et al.: Self-
expandable metallic stents for palliation of patients with
malignant gastric outlet obstruction caused by stomach can-
cer.  World J Gastroenterol 2007, 13:916-920.
BMC Gastroenterology 2009, 9:45 http://www.biomedcentral.com/1471-230X/9/45
Page 6 of 6
(page number not for citation purposes)
41. Kim JH, Song HY, Shin JH, Choi E, Kim TW, Jung HY, et al.: Metallic
stent placement in the palliative treatment of malignant gas-
troduodenal obstructions: prospective evaluation of results
and factors influencing outcome in 213 patients.  Gastrointest
Endosc 2007, 66:256-264.
42. Song GA, Kang DH, Kim TO, Heo J, Kim GH, Cho M, et al.: Endo-
scopic stenting in patients with recurrent malignant obstruc-
tion after gastric surgery: uncovered versus simultaneously
deployed uncovered and covered (double) self-expandable
metal stents.  Gastrointest Endosc 2007, 65:782-787.
43. Mutignani M, Tringali A, Shah SG, Perri V, Familiari P, Iacopini F, et al.:
Combined endoscopic stent insertion in malignant biliary
and duodenal obstruction.  Endoscopy 2007, 39:440-447.
44. Lowe AS, Beckett CG, Jowett S, May J, Stephenson S, Scally A, et al.:
Self-expandable metal stent placement for the palliation of
malignant gastroduodenal obstruction: experience in a
large, single, UK centre.  Clin Radiol 2007, 62:738-744.
45. Maetani I, Isayama H, Mizumoto Y: Palliation in patients with
malignant gastric outlet obstruction with a newly designed
enteral stent: a multicenter study.  Gastrointest Endosc 2007,
66:355-360.
46. Hosono S, Ohtani H, Arimoto Y, Kanamiya Y: Endoscopic stenting
versus surgical gastroenterostomy for palliation of malig-
nant gastroduodenal obstruction: a meta-analysis.  J Gastroen-
terol 2007, 42:283-290.
47. Hayashi K, Okayama Y, Gotoh K, Ohara H, Sano H, Nakazawa T, et
al.: Clinical evaluation of metallic stenting for malignant duo-
denal obstruction using covered self-expandable metallic
stent.  Digestive Endoscopy 2005, 17(3):263-268.
48. Song HY, Shin JH, Yoon CJ, Lee GH, Kim TW, Lee SK, et al.: A dual
expandable nitinol stent: experience in 102 patients with
malignant gastroduodenal strictures.  J Vasc Interv Radiol 2004,
15:1443-1449.
49. Mehta S, Hindmarsh A, Cheong E, Cockburn J, Saada J, Tighe R, et al.:
Prospective randomized trial of laparoscopic gastrojejunos-
tomy versus duodenal stenting for malignant gastric outflow
obstruction.  Surg Endosc 2006, 20:239-242.
50. Kostopoulos PP, Zissis MI, Polydorou AA, Premchand PP, Hendrickse
MT, Shorrock CJ, et al.: Are metal stents effective for palliation
of malignant dysphagia and fistulas?  Dig Liver Dis 2003,
35:275-282.
51. Fayers PM, Machin D: Quality of Life. The assessment, analysis and inter-
pretation of patient reported outcomes 2nd edition. Chichester, West
Sussex P019 8SQ, England: John Wiley and Sons Ltd; 2007. 
52. Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M: Assess-
ing health-related quality of life in palliative care: comparing
patient and physician assessments.  Eur J Cancer 2006,
42:1159-1166.
53. McPherson CJ, ddington-Hall JM: Judging the quality of care at
the end of life: can proxies provide reliable information?  Soc
Sci Med 2003, 56:95-109.
54. Maetani I, Ukita T, Tada T, Ikeda M, Seike M, Terada H, et al.: Gastric
emptying in patients with palliative stenting for malignant
gastric outlet obstruction.  Hepatogastroenterology 2008,
55:298-302.
55. Abrahamsson H: Gastrointestinal motility disorders in patients
with diabetes mellitus.  J Intern Med 1995, 237:403-409.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/9/45/pre
pub
II

ORIGINAL ARTICLES
Patient-reported outcomes in palliative gastrointestinal stenting:
a Norwegian multicenter study
Lene Larssen • Asle W. Medhus • Marianne J. Hjermstad • Hartwig Ko¨rner •
Tom Glomsaker • Taran Søberg • Dagﬁnn Gleditsch • Øistein Hovde •
Arild Nesbakken • Jan K. Tholfsen • Knut Skreden • Truls Hauge
Received: 9 July 2010 / Accepted: 14 March 2011 / Published online: 13 April 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Background The clinical effect of stent treatment has
been evaluated by mainly physicians; only a limited
number of prospective studies have used patient-reported
outcomes for this purpose. The aim of this work was to
study the clinical effect of self-expanding metal stents in
treatment of malignant gastrointestinal obstructions, as
evaluated by patient-reported outcomes, and compare the
rating of the treatment effect by patients and physicians.
Methods Between November 2006 and April 2008, 273
patients treated with SEMS for malignant GI and biliary
obstructions were recruited from nine Norwegian hospitals.
Patients and physicians assessed symptoms independently
at the time of treatment and after 2 weeks using the
European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 questionnaire supplemented
with speciﬁc questions related to obstruction.
Results A total of 162 patients (99 males; median
age = 72 years) completed both assessments and were
included in the study. A signiﬁcant improvement in the
mean global health score was observed after 2 weeks (from
9 to 18 on a 0–100 scale, P\ 0.03) for all stent locations.
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Both patients and physicians reported a signiﬁcant reduc-
tion in all obstruction-related symptoms ([20 on the 0–100
scale, P\ 0.006) after SEMS treatment. The physicians
reported a larger mean improvement in symptoms than did
the patients, mainly because they reported more severe
symptoms before treatment.
Conclusion SEMS treatment is effective in relieving
symptoms of malignant GI and biliary obstruction, as
reported by patients and physicians. The physicians, how-
ever, reported a larger reduction in obstructive symptoms
than did the patients. A prospective assessment of patient-
reported outcomes is important in evaluating SEMS
treatment.
Keywords Stents  Palliative care  Gastrointestinal
cancer  Biliary tract neoplasm  Outcome assessment 
Quality of life
Palliative treatment with self-expanding metal stents
(SEMS) is regarded as a safe and highly effective proce-
dure for relief of symptoms caused by malignant obstruc-
tions of the gastrointestinal (GI) tract [1–8]. Most studies
concerning treatment with SEMS, whether randomized,
comparative, or merely descriptive, focus on technical
success (e.g., correct deployment of the stent), clinical
success (restored passage), procedure-related complica-
tions, and cost-effectiveness. Typically, the clinical out-
comes of SEMS treatment have been evaluated by the
physician [9]; only a few prospective studies reported
repeated symptom assessments by the patient [10–16].
Since patients’ and physicians’ ratings of treatment effects
do not always correspond well, palliative treatment efforts
such as SEMS for malignant GI obstructions should be
evaluated by individual outcome measures reported by the
patients as well as by the physicians [17–22].
The main objective of this multicenter study was to use
patient-reported outcomes to evaluate the treatment effects
of SEMS on quality of life (QoL) and symptoms related to
malignant GI and biliary obstruction. An additional aim of
the study was to compare patient- and physician-reported
evaluations of the treatment’s effects.
Materials and methods
Nine Norwegian hospitals performing SEMS treatment for
GI obstructions participated in the present study. The
inclusion period was from November 2006 to April 2008.
Patients were eligible for consecutive inclusion according
to the following criteria: (1) symptoms related to malignant
GI obstruction, (2) indication for treatment with all types of
metal stents established, (3) ﬂuency in oral and written
Norwegian, and (4) cognitive capability to complete the
questionnaires. Patients who received their colonic stent as
a ‘‘bridge to surgery’’ (i.e., to relieve the acute obstruction
prior to elective surgery) and underwent bowel resection
within 2 weeks after stent placement were not asked to
complete the questionnaire after 2 weeks and were thus not
included in the analyses. The study was approved by the
Regional Committee for Medical Research Ethics in
Southern Norway and the Data Protection Supervisor at
Oslo University Hospital, Ulleva˚l. All patients received
oral and written information about the study. Written
informed consent was obtained from all participants.
Stent procedure
All stents were deployed endoscopically under ﬂuoroscopic
guidance. Both covered and uncovered stents were used for
esophageal and biliary stent treatment, while uncovered
stents were used in other locations.
Assessment of patient-reported outcomes
The European Organisation for Research and Treatment of
Cancer Core Quality of Life Questionnaire, EORTC QLQ-
C30, version 3.0 [23], was used to assess patient-reported
outcomes, supplemented with selected questions from
other relevant EORTC organ- and disease-speciﬁc modules
(http://www.eortc.be/). The EORTC QLQ-C30 is a cancer-
speciﬁc 30-item self-reporting questionnaire consisting of
both multi-item scales and single-item measures. These
include ﬁve functional scales (i.e., physical, role, cognitive,
emotional, and social), three symptom scales (i.e., fatigue,
nausea/vomiting, and pain), and six single items (i.e.,
dyspnea, insomnia, appetite loss, constipation, diarrhea,
and ﬁnancial problems), as well as two questions where the
patients assessed their overall health and QoL on a scale
from 1 to 7. Combining these two scores resulted in a
global health score.
EORTC recommends that organ-speciﬁc modules be
used in addition to the core questionnaire to capture diag-
nosis- or treatment-speciﬁc problems. For the purpose of the
present study, a selection of questions was made from the
relevant organ-speciﬁc modules to reduce the respondent’s
burden and to focus on speciﬁc problems pertaining to the
different diagnostic or stent groups. Questions to be
answered by the patients receiving esophageal, biliary, and
colonic stents were selected from the stomach module
EORTC QLQ-STO22 [24], the pancreatic module EORTC
QLQ-PAN26 [25], and the colorectal module EORTC
QLQ-CR38 [26], respectively (Table 2). Patients who
received gastroduodenal stents did not answer any
Surg Endosc (2011) 25:3162–3169 3163
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additional questions as their main obstruction-related
symptoms, nausea and vomiting, were speciﬁcally addres-
sed by the core questionnaire.
Higher scores on the symptom scales and single items
from the core questionnaires and the organ-speciﬁc mod-
ules indicated more severe symptoms, while higher scores
on the functional scales indicate better functioning. All
items were to be answered on an ordinal scale ranging from
1 (‘‘Not at all’’) to 4 (‘‘Very much’’), except for the two
modiﬁed visual analog scales assessing global health and
QoL; they ranged from 1 to 7. The time frame was the past
7 days. Scale and item scores were transformed into a
continuous scale from 0 to 100, as described in the EORTC
Scoring Manual [27]. A mean score difference of 5–10 is
usually regarded as a small but clinically noticeable change
for the patients, a change between 10–20 as moderate, and
[20 as a large clinical change [28, 29].
Administration of questionnaires
All assessments were performed twice, at inclusion (-2
to ?1 day before/after the procedure) and 2 weeks after
treatment. The questionnaire was administered to the
study participants upon admission by the treating physi-
cian or a study nurse. The same questionnaire was given
to the patients when leaving the hospital. The patients
were instructed to complete the second questionnaire
2 weeks after stent treatment and return it by mail. The
2-week time span between assessments was chosen to
reach the maximum effect of the stent treatment and
reduce the impact of disease progression. To reduce the
inﬂuence of recall bias, the patients had to complete the
initial questionnaire no later than the day after the pro-
cedure and the second questionnaire no later than 3 weeks
after treatment. The physicians assessed the same organ-
speciﬁc symptoms at inclusion and the second assessment
at hospital discharge or 2 weeks after stent treatment if
the patient was still hospitalized. The same physician was
responsible for the before and after assessment of
symptoms.
Statistical analysis
Power calculations were based on a mean change of 10
with a standard deviation (SD) of 15 of global health,
with 90% power and a 5% level of signiﬁcance, which
yielded a sample size of 26 patients in each of the
treatment groups for the four stent locations. Wilcoxon
signed-rank test with 5% signiﬁcance level was used
when evaluating changes of symptoms before and after
treatment. Statistical analyses were performed using SPSS
16.0 (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
A total of 273 patients were eligible for inclusion in the
study, varying from 2 to 105 patients at the nine partici-
pating centers. Two hundred thirty-eight (87%) patients
completed the questionnaire prior to the stent procedure,
and 162 (68%) of these completed both questionnaires.
Twenty-seven patients did not return the second form for
unknown reasons (Fig. 1). Ninety-nine males and 63
females with a median age of 72 years were included.
Clinical and demographic characteristics are given in
Table 1. The most frequent diagnoses were cancer of the
colon and pancreas. Of the 18 patients with gastric cancer
who received stents, eight had obstructions located in the
cardia ventriculi and were treated with esophageal stents.
Ten patients had gastric outlet obstruction and were treated
with duodenal stents.
Patient-reported outcomes
Patients reported a clinically and statistically signiﬁcant
reduction in all obstruction-related symptoms in all four
stent locations, with a mean reduction of at least 20
(P\ 0.02). Furthermore, a clinically and statistically sig-
niﬁcant improvement in global health function (P\ 0.03)
was observed in all treatment groups. Additionally, various
other symptoms improved signiﬁcantly: nausea/vomiting
(colon and biliary), appetite loss (biliary and gastroduo-
denal), pain (gastroduodenal and colonic), and constipation
(colonic) (Tables 2, 3, 4, and 5). The total numbers of
patients experiencing symptomatic improvement C 20,
improvement\ 20, or worsening are reported in Table 6.
The scorings from patients who completed the pre-
treatment questionnaire before treatment were similar to
those from patients who completed it the day after treat-
ment. Sixty-four patients (40%) completed the ﬁrst
assessment the day after stent insertion because of emer-
gency stent treatment or pronounced symptoms before
treatment. The rate of missing items was low, 0.9 and 1.0%
in the two assessments, respectively. For the multi-items
scales, missing values were assigned according to a stan-
dard scoring procedure (EORTCs scoring manual, [27]) by
replacing missing items with the scale mean values, pro-
vided that half or more of the scale items were completed.
Comparison of symptoms evaluated by patients
and physicians
When comparing the patients’ and physicians’ scores, a
signiﬁcant difference in the answers of six of seven
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questions before treatment was found, whereby the physi-
cians indicated symptoms as more pronounced than the
patients (P\ 0.02). However, when comparing the post-
treatment evaluation, the scores tended to be similar (a
statistically signiﬁcant difference was found for two
questions, see Table 7). When evaluating the clinical effect
as an improvement in obstructive symptoms, the physicians
reported a larger mean reduction in obstructive symptoms
and, thus, a better treatment effect as compared to the
patients.
The median hospital stay was 4 days (range = 0–64).
Therefore, physicians completed their second symptom
assessment\7 days after the ﬁrst registration in (131/162)
81% of the cases. The patients completed their second
assessment of symptoms after 2 weeks (assessing symp-
toms between days 7 and 14).
Short-term outcome/complications
During the ﬁrst week, 12 of 162 patients (7%) experienced
complications: three nonfunctional stents, two stent migra-
tions, two bleeding episodes, two episodes of cholangitis,
one tracheal-esophageal ﬁstula, one stent obstruction by
food impaction, and one stent obstruction by tumor over-
growth. There was no procedure-related mortality.
Discussion
This study is one of very few that evaluates the symp-
tomatic effect of palliative GI stenting based on patient-
reported outcomes. Furthermore, to our knowledge it is the
ﬁrst to compare patients’ and physicians’ assessments of
the symptomatic effect of SEMS treatment. The present
study demonstrates that the majority of patients found
treatment with SEMS effective in relieving obstructive
symptoms in all GI tract locations. Additionally, patients
reported a signiﬁcant clinical improvement in global health
after 2 weeks for all four stent locations. The physicians
tended to evaluate pretreatment symptoms as more severe
than did the patients. The postprocedure scorings were
more similar.
This study shows that treatment with SEMS is effective
in relieving symptoms related to malignant GI obstruction.
Fig. 1 Flowchart showing the selection of the 162 patients included in this study
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Our conclusion is strengthened by the fact that patients in this
study were treated at small local centers, not large expert
centers. SEMS as palliative principle seems to be effective
independent of location. With regard to the symptomatic
effect on esophageal and gastric outlet obstructions,
our ﬁndings are in accordance with previous studies.
Additionally, were we able to ﬁnd signiﬁcantly improved
general well-being and better QoL, which most previous
studies had not been able to document [10, 12]. A study of
colon obstruction using patient-reported outcomes ended
early and was therefore not able to make a conclusion [30].
That physicians’ and patients’ perceptions of symptoms
differ is in line with previous studies in palliative medicine
that compared physicians and patients, although underes-
timation of patients’ symptoms by physicians is more
common [17–21]. We do not know the reasons for the
discrepancies in scoring found in our study; but one plau-
sible explanation may reﬂect the enthusiasm of the physi-
cians performing these procedures and their needs to justify
the indication. The study was not designed to clarify this
question.
Table 1 Clinical and demographic characteristics of 162 patients
treated by self-expanding metal stents for malignant gastrointestinal
obstruction
Age [median (range)] 72 (33–93)
Gender M/F 99/63
Survival [median (range)] (days) 111 (15–535)
Diagnoses
Colon cancer 49 (30%)
Pancreatic cancer 41 (25%)
Gastric cancer 18 (11%)
Esophageal cancer 28 (17%)
Bile duct cancer 9 (6%)
Other malignanciesa 17 (11%)
Other palliative treatment
Chemotherapy (during day 0–14) 18 (11%)
Radiotherapy (during day 0–14) 7 (4%)
Stent locations
Esophageal 41 (25%)
Gastroduodenal 33 (20%)
Biliary 40 (25%)
Colon 48 (30%)
a Breast cancer, n = 1, lymphoma, n = 1; lung cancer, n = 3;
prostate cancer, n = 2; hepatocellular carcinoma, n = 1; gallbladder
cancer, n = 1; thyroid cancer, n = 1; papillary cancer, n = 1; ovar-
ian cancer, n = 3; duodenal cancer, n = 1; malignant melanoma,
n = 2
Table 2 Scores from EORTC C30a and selected obstruction-related questions from EORTC OES 18 given by 41 patients treated with
esophageal stents
Before After Difference P value
Global health functionb 30.0 (18.0) 39.1 (26.1) 9.2 (26.4) 0.03
Symptom scalesa,c
Nausea/vomiting 37.8 (31.0) 33.7 (31.7) 4.1 (39.6) 0.49
Pain 43.5 (29.6) 51.2 (31.5) -7.7 (34.6) 0.20
Single itemsc
Appetite loss 69.1 (38.3) 61.8 (39.1) 7.3 (41.8) 0.31
Organ-speciﬁc questions from EORTC OES 18c
Have you had problems eating solid food? 86.8 (26.3) 51.0 (40.1) 36.0 (51.6) \0.001
Have you had problems eating liquidized or soft food? 63.1 (35.3) 30.0 (37.3) 32.4 (52.3) 0.001
Have you had problems drinking liquids? 38.6 (36.8) 16.7 (26.5) 22.0 (41.2) 0.002
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was made; no signiﬁcant change was found in the excluded scores
b Scale from 0 to 100; high scores represent higher level of functioning
c Scale from 0 to 100; high scores represent more severe symptoms
Table 3 EORTC C30a results from 33 patients treated with gastro-
duodenal stents
Before After Difference P value
Global health
functionb
22.0 (19.3) 38.4 (26.4) 16.4 (24.8) \0.001
Symptom scalesb
Pain 57.6 (28.6) 39.9 (36.3) 17.7 (36.3) 0.014
Nausea/vomiting 63.1 (31.1) 30.3 (27.5) 32.8 (38.7) \0.001
Single itemsb
Appetite lossc 81.8 (25.1) 65.7 (37.7) 16.2 (34.5) 0.013
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was
made; no signiﬁcant change was found in the excluded scores
b Scale from 0 to 100; high scores represent more severe symptoms
c Scale from 0 to 100; high scores represent higher level of overall
functioning
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The physicians completed the second questionnaire
earlier than the patients (earlier than day 7 for 81% of the
patients). The study protocol did not include a scheduled
follow-up after stent treatment. The patients were often
severely ill, with long travelling distance to hospital, and an
extra hospital visit to allow the physician to perform a
symptom assessment was hence not included in the follow-
up. As the hospital stay related to the stent procedure
usually was of short duration, the physicians’ scoring often
had to be performed at discharge from hospital. However,
it is likely that the questionnaire’s 1-week time format
reduced the inﬂuence of the discrepancy of when the
physicians and patients did the second assessment.
Although there were signiﬁcant improvements for the
group in total, there was interindividual variation and some
patients did not experience improvement in their obstruc-
tive symptoms. A review of the medical charts revealed
that absence of symptomatic improvement often could be
explained by dysfunctional stents, migrations, infections,
pain, or intercurrent diseases during the ﬁrst 2 weeks. This
represented a limited number of patients and separate
subanalyses were not performed. Furthermore, ongoing
treatment with other modalities (e.g., chemotherapy) can
potentially inﬂuence symptom scoring negatively. We
found no signiﬁcant difference in the scorings of the 25
patients who received chemo- and/or radiation therapy
during the assessment period.
Table 4 Scores from EORTC C30a and selected obstruction-related
questions from EORTC PAN26 from 40 patients treated with biliary
stents
Before After Difference P value
Global health
functionb
30.4 (25.9) 48.3 (28.0) 17.9 (34.3) 0.003
Symptom scalesc
Pain 48.3 (36.2) 28.8 (25.0) 19.6 (31.8) 0.001
Nausea/vomiting 35.0 (30.8) 21.3 (23.3) 13.8 (28.7) 0.005
Single itemsc
Appetite loss 61.7 (41.0) 45.8 (41.8) 15.8 (32.0) 0.007
Organ-speciﬁc questions from EORTC PAN 26c
Have you been
itching?
46.6 (39.1) 23.3 (32.2) 23.3 (51.3) 0.01
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was
made; no signiﬁcant change was found in the excluded scores
b Scale from 0 to 100; high scores represent higher level of overall
functioning
c Scale from 0 to 100; high scores represent more severe
Table 5 Scores from EORTC C30a and selected questions from EORTC CR38 from 46 patients treated with colon stents
Before After Difference P value
Global health functionb 38.0 (24.8) 48.7 (23.7) 10.7 (24.5) 0.009
Symptom scalesa, c
Pain 49.3 (33.9) 28.4 (30.0) 20.9 (39.0) 0.001
Nausea /vomiting 29.4 (34.1) 13.8 (21.5) 15.6 (33.6) 0.003
Single itemsc
Appetite loss 45.4 (40.8) 31.9 (35.4) 13.5 (45.4) 0.04
Constipation 53.9 (43.7) 24.8 (32.2) 29.1 (46.0) \0.001
Diarrhea 37.6 (37.2) 45.4 (33.6) -7.8 (45.7) 0.26
Organ-speciﬁc questions from EORTC CR38c
Have you had abdominal pain? 53.6 (38.2) 32.6 (28.5) 21.0 (37.4) \0.001
Have you felt bloated? 67.4 (36.2) 27.5 (30.0) 40.0 (44.8) \0.001
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was made; no signiﬁcant change was found in the excluded scores
b Scale from 0 to 100; high scores represent higher level of overall functioning
c Scale from 0 to 100; high scores represent more severe symptoms
Table 6 Patient-reported symptomatic effect of stent treatment
Number of patients with clinical
effect on C1 symptoms
Number of patients with no
effect or worsening of symptoms
Esophageal stent 34 (81%) 8 (19%)
Gastroduodenal stent 16 (48%) 17 (52%)
Biliary stent 20 (50%) 20 (50%)
Colonic stent 33 (69%) 15 (31%)
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Our study did not identify subgroups of patients that
regularly did not beneﬁt from SEMS treatment and,
therefore, should have received alternative palliative
treatment. This might be due to the relatively low number
of patients included.
Seventy-six patients completed only the ﬁrst question-
naire. However, as shown in Fig. 1, only 27 patients failed
to complete the second questionnaire for unknown reasons.
It is possible that these patients did not experience the
expected effect of the stent treatment and that this lack of
data could represent a selection bias. However, we know
that these 27 patients did not differ in age, pretreatment
global health, or survival from the 162 repliers. Three of
these 27 patients experienced dysfunctional stents and
needed reinterventions during the ﬁrst 2 weeks, which
might have inﬂuenced their opinion of stent function. Three
patients experienced cholangitis and/or pancreatitis
immediately after biliary stenting but had functional stents.
For the remaining 21 of the 27 patients, there was not
sufﬁcient information in their medical records to explain
why they did not return their second questionnaire.
Conclusion
SEMS treatment is effective in relieving symptoms of
malignant GI and biliary obstruction, according to assess-
ment by both patients and physicians. This study demon-
strates a signiﬁcant difference in how the physicians and
patients evaluate treatment effects and thereby the impor-
tance of taking patient-reported outcomes into account
when evaluating clinical palliative interventions. Future
studies evaluating SEMS treatment should include pro-
spective assessment of patient-reported outcomes to
increase our knowledge about the efﬁcacy of this treatment.
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